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ABSTRACT 
 
Aims 
The objectives of this study were to evaluate the incidence, risk factors, and outcome of 
acute kidney injury (AKI) in adult intensive care unit (ICU) patients in Finland, and to test 
the ability of two new biomarkers to predict AKI, renal replacement therapy (RRT), and 
90-day mortality in a large group of unselected ICU patients.  
 
Materials and methods 
A prospective, observational FINNAKI-study was conducted in 17 Finnish ICUs and all 
admitted patients were screened for eligibility during the study period of five months (1st of 
September 2011 to 1st of February 2012). All adult emergency admissions and elective 
admissions with an expected stay over 24 hours were included. AKI was defined with the 
Kidney Disease: Improving Global Outcomes (KDIGO) criteria and the patients were 
screened for five days. Urine samples were collected from all eligible patients. Study data 
were collected from the Finnish Intensive Care Consortium (FICC) prospective database 
and with a study Case Report Form (CRF).  
 
Study I included all patients in the FINNAKI study and evaluated the incidence and risk 
factors for AKI and reported the 90-day mortality of patients with AKI.  
 
In study II, urine neutrophil gelatinase-associated lipocalin (NGAL) was measured from a 
set of patients with samples available from the first 24 hours of admission. The analyses 
were performed with a commercially available ELISA kit (BioPorto®). The ability of NGAL 
to predict AKI, RRT, or 90-day mortality was evaluated.  
 
In Study III, urine interleukin-18 (IL-18) was analysed from a set of patients with a sample 
available from ICU admission. The analyses were performed with a commercially available 
ELISA kit (Cusabio Biotech®). This study evaluated the ability of IL-18 to predict AKI, 
RRT, or 90-day mortality. 
 
Study IV evaluated the long-term outcome of patients with AKI by assessing their 6-month 
mortality and the survivors’ health-related quality of life (HRQol) at ICU admission and 
six-months later with the EQ-5D questionnaire. Study IV included FINNAKI study centres 
that had a follow-up-rate of over 70% concerning the EQ-5d data.  
 
Main results 
Study I included 2901 patients, of whom 1141 (39.3%, 95% Confidence interval, CI 37.5 - 
41.1%) developed AKI during the first five days. The proportions of patients in the different 
stages of AKI were 499/2901 (17.2%, 95% CI 15.8 - 18.6%) in stage 1, 232/2901 (8.0%, 95% 
CI 7.0 – 9.0%) in stage 2, and 410/2901 (14.1%, 95% CI 12.8 – 15.4%) in stage 3. RRT was 
initiated for 272/2901 (9.4%, 95% CI 8.3% - 10.5%) patients during the first five days. The 
population-based incidence of AKI was 746 (95% CI 717 - 774) per million adults per year. 
Patients that developed AKI were older and more severely ill, and had more chronic 
comorbidities than patients without AKI. Hypovolaemia prior to ICU admission, 
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administration of diuretics or colloids (HES or gelatin) prior to ICU admission, and 
chronic kidney disease were independent risk factors for AKI. Of the 1141 AKI patients, 
385 (33.7%, 95% CI 30.9 – 36.5%) died within 90-days.  
 
Study II included 1042 patients from 15 study centres. In this population, urine NGAL 
predicted AKI with an AUC (95% CI) of 0.733 (0.701 – 0.765), RRT with an AUC (95% CI) 
of 0.839 (0.797 – 0.880), and 90-day mortality with an AUC (95% CI) of 0.634 (0.593 – 
0.675). 
  
Study III included 1439 patients from 17 study centres. Urine IL-18 predicted the 
development of AKI with an AUC (95%CI) of 0.586 (0.546-0.627), initiation of RRT with 
an AUC (95% CI) of 0.655 (0.572-0.739), and 90-day mortality with an AUC (95% CI) of 
0.536 (0.497-0.574). 
 
Study IV included 1568 patients from 10 study centres of whom 1190 were alive at six 
months. Of the AKI patients, 224/635 (35.3%, 95% CI 31.5 - 39.1%) died during six 
months. Of the six-month survivors, 959/1190 (80.6%) answered the EQ-5D. The EQ-5D 
index for AKI patients at six-months (0.676, Interquartile range, IQR 0.520-1.00) was 
lower than for the age- and sex-matched general population (0.826, IQR 0.812-0.859) but 
equal to that of patients without AKI (0.690, IQR 0.533-1.00). There was no significant 
change in the EQ-5D over six-months for either patient group (mean change 0.024 for 
patients with AKI and 0.017 for patients without AKI). Despite their measured lower 
HRQol, AKI patients evaluated their quality of life to be as good as that of the age- and sex-
matched general population at six-months after the ICU treatment: EQ-5D visual analogue 
scale (IQR) for patients with AKI was 70 (50-83), and for the general population 69 (68-
73).  
 
Conclusions 
Incidence of AKI among critically ill patients was high. Hypovolaemia, diuretics, and 
colloids prior to ICU admission were independently associated with the development of 
AKI. In this population, urine NGAL was statistically associated with the need to initiate 
RRT, but the transformation of this result into clinical practice is complicated. Urine 
NGAL lacks power to predict AKI or 90-day mortality. Urine IL-18 has no adequate power 
to predict AKI, RRT, or 90-Day mortality in critically ill adult patients. AKI is associated 
with significantly increased 90-day and 6-month mortality. The HRQol of all ICU patients 
was lower than that of the age- and sex-matched general population already before ICU 
treatment. This HRQol did not change during critical illness or during a six-month follow 
up. Despite their lower HRQol, AKI patients felt their health was equal to that of the 
general population.  
 
Keywords 
Acute kidney injury, critical illness, health-related quality of life, interleukin 18, mortality, 
neutrophil gelatine-associated lipocalin, renal replacement therapy  
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1. INTRODUCTION 
 
 
Acute kidney injury (AKI) refers to a syndrome encompassing kidney damage from mild 
injury to total loss of function that seriously disturbs the homeostasis of fluid and 
electrolyte balances1.  
 
A uniform definition for acute kidney injury has existed only since 2004, when the Acute 
Dialysis Quality Initiative (ADQI) proposed the Risk, Injury, Failure, Loss, End-stage 
kidney disease (RIFLE) criteria for AKI2. Since then two modifications of the RIFLE: Acute 
Kidney Injury Network (AKIN) (2007)3, and Kidney Disease: Improving Global Outcomes 
(KDIGO) (2012)1 have emerged. All of the three modern definitions are based on changes 
in serum or plasma creatinine (Cr) and urine output (UO).  
 
Clinical symptoms may be scarce in the early stages of AKI. As the kidney injury progresses 
and affects the glomerular filtration rate (GFR) Cr starts to rise. Oliguria or anuria may 
develop early, but sometimes the UO remains intact for quite long. Later in the course of 
AKI the severely diminished GFR manifests as electrolyte and acid-base disturbances, 
most often as elevated potassium and acidosis.  
 
Though described already in 19414 after limb crush injuries, pathogenesis of AKI is still 
poorly understood. Several different pathways have been proposed and studied; none of 
which seems to explain the big picture alone5-8. The arising consensus suggests that AKI is 
a syndrome with several different predisposing factors and mechanisms of 
pathophysiology. A growing amount of data supports the idea that risk for AKI increases 
with a growing “burden of illness” whether chronic or acute1.  
 
The traditional division of kidney failure to pre- and post-renal causes has been widely 
abandoned as the complex nature of the kidney injury syndrome has unfolded1. Extra-
renal causes, without actual kidney damage, such as depletion of fluids or urinary track 
obstruction naturally still exist but are rare causes for AKI in the intensive care 
environment. Also these causes, when identified, are quite easy to treat and usually 
without long-term damage to the kidney or other organs. In the ICU, AKI is usually 
multifactorial with both chronic conditions and acute events contributing to the 
development of kidney injury9.  Sepsis is the most common single underlying cause for 
AKI10.  
 
In the diagnosing and staging of AKI, Cr and UO act as surrogates for glomerular filtration 
rate, however prominent weaknesses in both as kidney injury markers exist11-13. A vigorous 
search for new kidney injury biomarkers has been going on for several years. A hope of 
easily measurable markers that would be more sensitive and specific to actual injury in the 
kidneys, would react earlier in the course of AKI, and would be less prone to bias in 
different physiological situations14 remains.  
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The incidence of AKI in Finland is unknown. In studies evaluating the incidence of AKI 
defined by any of the three current classifications, 11%15 to 67%16 of ICU patients developed 
AKI depending on the population studied and the study design. No studies using the 
newest KDIGO criteria exist.  
 
AKI has significant consequences. It is associated with morbidity17 and permanent loss of 
kidney function18. All severity stages of AKI are associated with significantly higher short-19 
and long-term mortality20.  AKI increases hospital expenses up to two-fold21 and achieving 
quality adjusted life years in the treatment of AKI patients is expensive22. No prospective 
multicentre studies have evaluated the outcome of ICU patients with acute kidney injury in 
Finland.   
 
The aim of this study was to evaluate the nationwide incidence of ICU treated AKI, search 
for risk factors associated with the development of AKI, assess two promising new AKI 
biomarkers (urine NGAL and urine IL-18), and to study the outcome of patients with AKI. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Definition of acute kidney injury (AKI)  
 
Acute kidney injury is any insult to the kidney, resulting in sudden loss of function leading 
to disruption of fluid and electrolyte homeostasis. The visible and measurable symptoms of 
AKI include oliguria or anuria and accumulation of products normally excreted by the 
kidneys such as Cr, urea, and potassium, which as the situation progresses leads to 
acidosis8. 
 
The first consensus criteria for AKI (RIFLE, Risk, Injury, Failure, Loss, End-stage) were 
proposed in 20042, and supplemented with some changes by the Acute Kidney Injury 
Network resulting in the AKIN criteria3 a few years later. In 2012 KDIGO (Kidney Disease: 
Improving Global Outcomes) released the latest guidelines for diagnosing and staging 
AKI1. Figure 1 illustrates these three classifications for AKI. With the consensus criteria, 
the term acute kidney injury (AKI) replaced the formerly used acute renal failure (ARF). 
Defining a unified criteria was a vital improvement in the field of AKI, for over 35 different 
definitions for ARF were previously used23 making comparison of studies challenging. A 
modified RIFLE for small children and infants was published in 200724.                                       
 
Serum Cr concentration and urine output are the basis of all the three current criteria 
(Figure 1). In brief, the AKIN classification supplemented the RIFLE with a small change 
(≥26.5 µmol/l) in Cr as a criterion for stage 1 AKI, and narrowed the observation period for 
change in Cr to 48 hours. Data from comparison of RIFLE and AKIN, showed, however, 
that the two classifications partly identified different patients19. The KDIGO criteria was 
then developed aiming to correct this by combining elements from both previous 
classifications. According to data the Cr criteria seem to identify more patients having AKI 
than the UO criteria15,25, however some patients are only recognized with the UO 
criteria19,25,26. 
 
The traditional classification of AKI into pre-renal, post-renal, and intrinsic AKI has 
largely been abandoned due to lack of correlation with histopathological findings27, 
outcome28 or the current classification of AKI1.  
 
In some specific kidney disorders (e.g. acute interstitial and glomerular nephritis, some 
viral infections, and vasculitic illnesses) the clinical manifestation is similar to AKI, 
however, as kidney diseases with no current association to critical illness these conditions 
are out of the scope of this study.   
 
Due to the nature of the definition, AKI is a syndrome with extremely varying clinical 
manifestation from patients with a small and transitional rise in creatinine, to patients 
with total loss of kidney function.  
  15 
 
 
Figure 1. Risk, Injury, Failure, Loss, End-stage (RIFLE), Acute Kidney Injury Network (AKIN), and Kidney 
Disease: Improving Global Outcomes (KDIGO) criteria for diagnosing and staging AKI. RIFLE is presented 
without Loss- and End-stage- stages. Only one criterion (creatinine or urine output) needs to be filled per 
patient, and all patients are staged according to their worst stage. In AKIN the change in Cr must occur in 48 
hours. In RIFLE, AKI should occur within 7 days and be sustained for more than 24 hours. In KDIGO the 1.5-
fold change in Cr must be presumed to occur within 7 days. The ≥353.6 µmol/l change must include fulfilling 
stage 1 Cr criteria.  
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2.2. Measuring kidney function and damage 
 
2.2.1. Glomerular filtration rate 
 
The glomerular filtration rate (GFR) is the best measure for kidney function, and the 
normal values of GFR range from 90 - 130 ml per minute per 1.73 m2 29. Figure 2 shows the 
equation for calculating GFR. It can be determined indirectly with intravenously injected 
substances that are freely filtered through the glomeruli. The gold standard for measuring 
GFR is the inulin clearance30, but some other substances can also be used31,32. Measuring 
GFR with exogenous substances is too complicated and expensive for routine use, and the 
creatinine clearance (CrCl) is widely used and accepted as a surrogate33-36. CrCl can be 
computed from a collection of urine (24 hours) and Cr. Precise calculation of CrCl requires 
a steady state, which is rarely the case in critically ill patients37.  
 
 
 
 
 
 
Figure 2. Calculating the glomerular filtration rate (GFR) 
 
 
 
CrCl and hence GFR can be estimated from any of several equations of which the Cockroft-
Gault38, the Modification of Diet in Renal Disease (MDRD)29,39, and the CKD-EPI40 are the 
most relevant. These three equations are presented in Figure 3.  
 
The MDRD normalizes the results to body surface area and might be more accurate than 
the Cockroft-Gault41,42. CKD-EPI is the most recent equation shown to be superior in 
comparison to the MDRD40,43. However, the MDRD is the equation currently 
recommended by the Acute Dialysis Quality Initiative2. Usually the 4-variable modification 
of the MDRD is used44,45.  
 
In AKI studies CrCl/GFR equations (most often the MDRD46) are used to estimate a 
baseline creatinine for patients lacking it by back calculating with the assumption of a 
normal GFR of 75 ml/min / 1.73 m2. Using any of the equations to estimate GFR may lead 
to over- or underestimation of the incidence of AKI43,46-48.   
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Figure 3. a) The Cockroft-Gault38, b) The Modification of Diet in Renal Disease, MDRD (simplified 4-variable 
equation without urea and albumin45), and c) The CKD-EPI40 equations for estimating creatinine clearance or 
glomerular filtration rate. 
 
2.2.2. Creatinine and urine output 
 
The current classifications for AKI are based on Cr and urine output1-3. Though they are 
accepted as surrogates for GFR, both Cr and UO are prone to significant bias when used as 
markers for kidney function. 
 
Normal serum creatinine levels vary according to age, sex, race, muscle mass, medications, 
and fluid status11,12,49. In addition, Cr is not only freely filtered in the glomeruli, but also 
actively excreted by the tubules; this rate of excretion depends on the serum Cr 
concentration11,30. Cr is insensitive to changes in the GFR; the concentration of Cr starts to 
rise when half of the kidney function has already been lost50. Changes in Cr are therefore 
slow after an injury to the kidneys11. 
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The correlation of GFR and urine output is not linear. Urine output might be normal in 
AKI because of tubular injury and impaired concentration ability1,13. Low urine output can 
be a result of urinary track obstruction. In addition, diuretics or other medications may 
alter the diuresis. In very obese patients, the straightforward utilizations of urine output 
per weight (ml/kg/h) leads to overestimation of AKI1,13. 
 
2.2.3. Urea 
 
Urea, and especially the urea to Cr ratio, has been used as a marker of kidney function in 
the hope of differentiating between transitory azotaemia (pre-renal azotaemia) and actual 
kidney injury (formerly acute tubular necrosis)51. However, a recent study reported that 
the urea to Cr ratio is not useful in differentiating between different types of AKI52. Urea is 
freely filtered in the glomeruli, as is Cr, but it also has significant reabsorption. Nor is urea 
produced at a constant rate53. Furthermore, several other factors such as steroid 
administration, nutritional status, and diet might affect the blood urea levels54. Elevated 
urea is independently associated with increased mortality55 regardless of Cr and is 
included in many severity scores56.  
 
2.2.4. Urinalysis 
 
Chemical analysis of urine (fractional excretion of sodium and urea) and urine microscopy 
have traditionally been a part of the clinical evaluation for patients with kidney disorders57. 
Some data suggest that evaluating the urine sediment58, fractional excretion of sodium59, 
or fractional excretion of urea60 could differentiate between transient and persistent AKI, 
and predict worsening AKI or outcome61,62. However, urine sediment processing, any 
scoring systems, or appropriate timing of urinary microscopy in AKI diagnostics have not 
been standardized63.  
 
In several countries including Finland, urinalysis and urine microscopy performed by a 
nephrologist are no longer a part of the routine test pattern for acute kidney injury patients 
in the ICU64,65, except for routine differential diagnosis between, for e.g., infection and 
AKI. A growing burden of evidence suggests that urine microscopy or biochemistry have 
no value in discrimination between types of AKI66 or in predicting worsening AKI67. 
Recently, a multi-centre study in critically ill patients demonstrated poor ability of urinary 
indices to differentiate between transient and persistent AKI68. 
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2.3. Pathophysiology of AKI 
 
 
The pathophysiology of AKI is in many parts still unknown. Currently AKI is regarded as a 
complex, multi-etiological syndrome with several different pathophysiological 
mechanisms. Most of the current knowledge of pathophysiology of AKI comes from animal 
studies69. For many years, vasomotor disturbances and ischaemic injury were the main 
focus of attention in the study of aetiology of AKI8. Since then, growing knowledge on the 
mechanisms of AKI have shown that though important, ischaemic-reperfusion injury is 
only one of the mechanisms causing AKI70. 
 
2.3.1. Ischaemic-reperfusion injury 
 
The kidneys maintain their perfusion pressure and glomerular filtration rate in different 
haemodynamic situations very efficiently by autoregulation with the afferent and efferent 
arterioles in each glomerulus reacting to vasoconstrictive and vasodilatory factors7. In the 
autoregulation range, the afferent arteriole reacts to decreased perfusion pressure with 
vasodilatation. In situations where the autoregulation is disturbed, such as extreme global 
hypotension, vascular thrombosis, vascular clamping, or oxygen depletion the response is 
vasoconstriction and reduction of GFR8. However, significant periods of isolated warm 
ischemia are tolerated by the kidneys without sustained injury71. Reperfusion following 
ischemia is also damaging to the tissues and this type of damage is often called ischaemic-
reperfusion injury.  
 
In situations where autoregulation fails, depletion of adenosine triphosphate (ATP) follows 
initiating the complex mechanisms leading from ischemia to injury. Damage to the 
endothelium and release of nitric oxide (NO) seems to play a role in local imbalance of 
vasoactive substances72. These reactions are accompanied by metabolic changes8,73, 
activation of the coagulation system74, and an inflammatory reaction75. The damaged 
vascular endothelium leads to increased permeability76, and further increased leukocyte 
infiltration77. The damaged cells in the kidneys lose their cytoskeletal structure78 and 
release more proinflammatory and chemotactic substances that further enhance the 
reaction79.  
 
Obstruction of the tubules by cell casts and back leak of glomerular filtrate to capillaries 
may contribute to the injury80,81. Reperfusion injury further damages the cells via oxidative 
processes73. Most tubular cells, however, usually remain viable5,6,82. Both necrosis82 and 
apoptotic processes83 have been seen in the damaged kidney cells.  
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2.3.2. Septic AKI 
 
Sepsis is the most common predisposing factor for AKI in the critically ill9. Despite early 
assumptions84, septic AKI is far more complex than just ischaemic-reperfusion injury 
resulting from poor haemodynamics or low RBF70. It seems that septic AKI is 
multifactorial, and the mechanism of development may vary significantly between 
patients85,86. It is poorly understood why only a minority of sepsis patients have a classical 
tubular necrosis when assessed histopathologically87, and actually most renal tubular cells 
remain intact in septic AKI82. Most of the data on septic AKI have been derived from 
animal studies88.   
 
Animal models have suggested considerable variability in RBF in relation to systemic 
haemodynamic changes in sepsis89.  In a recent study systemic haemodynamics and RBF 
were measured noninvasively from septic patients showing constantly reduced RBF in 
comparison to cardiac output (CO)90. Also, in previous studies RBF and GFR have been 
poorly correlated6,85,91. Thus, the loss of GFR in septic AKI can occur in the presence of a 
normal or even hyperdynamic RBF, and because of disturbed autoregulation uncoupling of 
systemic haemodynamics and RBF occurs86.  
 
In sepsis the excessive systemic inflammatory reaction most likely plays a key role in the 
development of kidney injury and multiple organ failure92. The release of various 
inflammatory mediators, from pathogens and from immune cells, induces direct toxicity to 
tubular cells and triggers a complex cascade of inflammation89,93.  
 
At the cellular level, immunomodulators such as tumour necrosis factor α, Interleukin 6, 
and leukotrienes94 are suggested to cause apoptosis or even necrosis in tubular cells. In 
addition, the inflammatory stimulus induces the release of nitric oxide (NO) in response to 
endothelial damage causing disturbances in intrarenal hemodynamics95 and shunting in 
the periglomerular system. It has been suggested that excess dilatation of the efferent 
arteriole compared to the afferent arteriole96,97 would lead to “local hypotension” in the 
glomeruli and loss of GFR. In response, the renin-angiotensin-aldosterone (RAAA) 
system98 is activated leading to increased renal vascular resistance89, further decreasing 
RBF.  
 
Oxidant stress, mitochondrial dysfunction, and microcirculatory abnormalities have also 
been proposed as contributors to septic kidney injury, but the role of these mechanisms 
remains unclear86. 
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Figure 4. Schematic illustration of the pathogenesis of septic acute kidney injury. 
 
        
2.3.3. Nephrotoxins 
 
Several drugs and other substances frequently used in the ICU have direct or indirect 
effects on the kidneys. Indirect effects can be transmitted via influencing the systemic 
haemodynamics or modifying the pharmacokinetics of other drugs99. Direct damage to the 
kidneys can occur with various mechanisms: 1. by vasoconstriction (amphotericin, 
calcineurin inhibitors), 2. by altering the glomerular haemodynamic (non-steroidal anti-
inflammatory drugs, ACE-inhibitors, angiotensin-converting enzyme inhibitor), 3. by toxic 
injury to the tubules (aminoglycosides, amphotericin, calcineurin inhibitors, methotrexate, 
contrast media), 4. by inducing interstitial nephritis (acyclovir), 5. by distal tubular crystal 
formation (acyclovir, methotrexate), 6. by thrombotic microangiopathy (calcineurin 
inhibitors), or 7. by osmotically induced tubular damage (immunoglobulins, starch)100.    
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The excess release of myoglobin in rhabdomyolysis is damaging to the kidneys. Exact 
mechanisms of myoglobin induced AKI are unclear, but intrarenal vasoconstriction, direct 
and ischaemic tubule injury, and tubular obstruction are probably involved101. 
 
Tumour lysis syndrome (TLS) is a metabolic complication of cancer or treatment. In 
TLS the breakdown products of malignant cells induce hyperpotassinemia, 
hyperphosfataemia, hyperuricaemia, and hypocalcaemia, and often lead to AKI via calcium 
phosphate and uric acid crystallization102. Uric acid has more versatile effects by renal 
vasoconstriction, impaired autoregulation, oxidation, and inflammation103.  
 
2.3.4. Cardiorenal and hepatorenal syndromes 
 
Simultaneous and bidirectional heart-kidney and liver-kidney disorders are classified as 
cardiorenal (CRS) and hepatorenal syndromes (HRS). Kidney injury often follows heart 
failure and vice versa as CRS due to systemic neurohormonal responses, reduced cardiac 
output, elevated venous pressure, and the following hypotension104,105.  
 
The physiological consequences of acute liver failure are sepsis-like and often lead to acute 
kidney injury with multiple pathways including hypotension and renal ischemia, 
neurohormonal and immunological mechanisms, fluid accumulation and intra-abdominal 
hypertension due to ascites. The complex association between liver and kidney dysfunction 
is referred to as hepatorenal syndrome106,107.  
 
2.4. Novel biomarkers of AKI 
 
Due to known limitations in the current gold standard for AKI (creatinine and diuresis), 
new biomarkers to recognize AKI more sensitively, specifically, and earlier are needed. 
Figure 5 shows a timeline of developing AKI with regard to biomarkers. Both plasma and 
urine markers could be useful in AKI. Properties of an ideal biomarker would be:108,109 
 
1. must be generated by damaged, but not healthy cells. 
2. concentration in the body must be proportional to the extent of the damage 
3. should be expressed early after damage. 
4. concentration should decrease rapidly after the acute injury to enable therapeutic 
monitoring. 
5. should be easily, rapidly, and reliably measurable. 
 
The biomarker levels in plasma and urine increase by several different and coincidental 
mechanisms110: excess synthesis in extrarenal tissues or release by circulating cells leads to 
elevated levels in plasma. Biomarkers in plasma can then be filtered into urine at varying 
rates. In situations of injury, reabsorption of the marker in the tubules can be impaired. 
Some biomarkers are produced in the kidneys (in e.g. tubular cells) or can be released from 
cells migrated into the kidneys110.    
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Many potential biomarkers for AKI and adverse outcome associated with AKI have been 
studied to date108,111-113 none of which have so far proven to be superior to others. In recent 
years probably the most studied new biomarker for AKI has been neutrophil gelatinase-
associated lipocalin (NGAL) because of its biological plausibility and promising early 
studies114.  
 
Interleukin 18 (IL-18) is another promising biomarker with a known association to 
ischemic kidney injury and therefore a strong biological plausibility to be an AKI 
biomarker115,116. There is a lack of studies testing the predictive power of IL-18. The role of 
both these potential biomarkers in the ICU is unclear. 
 
 
 
Figure 5. Biomarkers in the evolution of AKI. The current definition of AKI is based on markers (Cr and UO) 
that show decline in GFR or kidney failure. Biomarkers that show increased risk and/or early damage are 
needed. GFR, Glomerular filtration rate. Adapted from Bellomo and colleagues70.  
 
 
2.4.1.Neutrophil-gelatinase associated lipocalin 
 
Neutrophil gelatinase-associated lipocalin (lipocalin-2) is a protein that was first found in 
human neutrophils117, but has since been identified from many different tissues such as the 
lungs, stomach, trachea, colon, and the kidneys118. NGAL has several functions of which 
only some are known adequately. NGAL is found both in plasma and urine.  
 
NGAL has an obvious role in the defence against microorganisms. It binds siderophores 
which are iron-binding molecules secreted by bacteria119. Furthermore, NGAL deficiency in 
animal models has led to increased sensitivity to certain bacterial infections120,121. NGAL 
also promotes epithelial cell differentiation122, and might be involved in the repair process 
after kidney injury123.  
 
Generally, NGAL levels increase in various stress situations like acute infections, heart 
failure, inflammation, and malignant conditions121,124-126. Plasma NGAL is elevated in 
septic patients regardless of their AKI status127,128.  
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What has made NGAL the focus of intense interest in the field of AKI is that it is one of the 
most upregulated genes in the early stages of ischaemic kidney injury, expressed mainly in 
the proximal tubules129, and shown to rise (2h) and peak (6h) early after the insult on 
patients developing AKI130. In addition, recent data suggests that NGAL may protect 
tubular cells from ischaemic injury131.  
 
Plasma NGAL was found in early studies to be very sensitive and specific to identify early 
kidney injury in children undergoing cardiac surgery with areas under the curve (AUC) of 
0.95132, 0.96133, and 0.998114 (AUC of > 0.9 is excellent, AUC of 0.75-0.9 is good and AUC 
of 0.5-0.75 is poor). Results in critically ill patients have not been as coherently positive134. 
Table 1 summarizes studies that have included more than 20 patients in the evaluation of 
the role of NGAL in critically ill adult patients.  
 
A growing body of evidence suggests that different molecular forms of NGAL exist135. 
Neutrophils predominately produce a 45 kDa homodimeric NGAL, and renal tubular cells 
predominately produce a 25 kDa monomeric NGAL. It is uncertain in what proportions 
each of the commercially available NGAL assays detect. Most of the monomeric NGAL in 
the urine is believed to originate from the renal tubular cells135-137. Immunosorbent assays 
that can identify the likely source of NGAL are beginning to emerge138. 
 
In a systematic review134 from 2009, NGAL associated with AKI with a good pooled AUC 
(95% CI) of 0.815 (0.732-0.892) across settings. The corresponding AUC (95% CI) in 
cardiac surgery patients was a little poorer, 0.775 (0.669-0.867), and in critically ill 
patients was 0.728 (0.615-0.834). Of the different settings, NGAL was most reliable in 
predicting AKI after contrast medium with an AUC of 0.894 (0.826-0.950). NGAL 
predicted AKI significantly better in children, AUC 0.930 (0.883-0.968), than in adults, 
AUC 0.782 (0.689-0.872). In the same systematic review, the NGALs ability to predict 
RRT was combined to an AUC of 0.782 (0.648-0.917) and to predict hospital mortality to 
an AUC of 0.706 (0.530-0.747). Urine NGAL was found to be more accurate than plasma 
NGAL (AUC 0.775 versus 0.837)134.   
  
Ten studies with more than 20 patients in each have evaluated the predictive power of 
NGAL in critically ill adult patients111,112,135,139-145. There are three studies with NGAL from 
urine111,112,145, three studies from plasma139,140,142, and four studies from both135,141,143,144. The 
numbers of patients in these studies vary from 25143 to 632141. All but two141,142 report the 
ability of NGAL to predict new AKI instead of already established AKI, and the observation 
period for the development of AKI ranges from 12 hours143 to 7 days111,112,139,146.  The AUCs 
for NGAL for AKI prediction in the ICU setting vary from 0.48144 to 0.956139.  
 
Seven of the ten studies also report AUCs for NGAL in the prediction of RRT112,135,139-142,144. 
The reported AUCs for NGAL with regards to initiation of RRT range from 0.26144 to 
0.89141. Six ICU studies111,112,135,140-142 have evaluated the association of NGAL to mortality, 
the chosen mortality time point ranging from 7 days112 to 90-days142. In only one of these 
studies evaluating mortality as an endpoint, the reported AUC was over 0.7 (0.83111 for 
NGAL in prediction of 14-day mortality).  
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A recent study investigated the predictive powers of the different forms of NGAL in ICU 
patients, and demonstrated that both plasma and urine NGAL currently have a poor ability 
to predict AKI, RRT, or mortality even when discriminating between the different 
molecular forms of NGAL135. 
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2.4.2.Interleukin 18 
 
Interleukin 18 (IL-18) is a member of the IL-1 cytokine family. It occurs intracellulary as an 
inactive precursor in monocytes and epithelial cells of the gastrointestinal tract115. The 
inactive form is activated by caspase-1, and then secreted mainly by macrophages or 
dendritic cells147. Free IL-18 in the cells is normally bound by IL-18 binding protein. The 
amounts of free IL-18 in the circulation are elevated with increasing imbalance between 
IL-18 and its binding protein after excess IL-18 production115. IL-18 promotes 
inflammation115, and has a role in many autoimmune diseases148, and ischaemic heart 
disease149. 
 
IL-18 is involved in ischaemic tubular necrosis as shown by animal studies in which IL-18-
blocked mice were protected against ischaemic AKI116,150. IL-18 is shown to rise 
significantly in patients with acute tubular necrosis compared to healthy controls, and 
patients with various other renal diseases (urinary track infection, prerenal azotaemia, 
chronic renal diseases, renal transplant patients)151. In cardiac surgery patients, IL-18 
started to rise 4-5h after cardiopulmonary bypass (CPB) and peaked at 12h152. IL-18 levels 
have been elevated in patients with sepsis, and especially in patients with gram positive 
infections153. 
 
The prognostic value of IL-18 in the prediction of AKI in an adult ICU setting has been 
investigated in five studies111,112,154-156. These studies all used urine IL-18 and are presented 
in Table 2. The AUC for IL-18 in the prediction of AKI ranges from 0.55112 to 0.73155.  
 
Only one adult ICU study reports an AUC for IL-18 in the prediction of RRT (AUC 0.73) 
with only 14 patients meeting the endpoint112. 
 
Four studies (two of the studies in Table 2, one in cardiac surgery patients and one in RRT-
patients) report IL-18 in association with mortality111,112,157,158 with AUCs ranging from 
0.53157 to 0.83111. One ICU study reported the association of IL-18 with hospital mortality 
in hazards ratio 2.32 (95% CI 1.2 – 4.4)155. A recent study of serum IL-18 found an 
independent association of IL-18 with hospital mortality158. 
 
In a meta-analysis from 2013 the pooled AUC (95% CI) for IL-18 across all settings in 
prediction of AKI was 0.70 (0.66-0.74)159, and in ICU patients 0.66 (0.62-0.70). In cardiac 
surgery patients IL-18 predicted AKI with a pooled AUC of 0.72 (0.68-0.76). Of the 
different settings, IL-18 predicted AKI best in children across settings: AUC 0.78 (0.75-
0.82). In these studies, 4-6 hours after cardiac surgery was the optimal time point to 
measure IL-18159 
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2.5. Risk factors for AKI 
 
In the ICU, AKI is usually multifactorial with several different insults affecting the kidneys 
in an additive way. The combined risk for each patient comprises both acute exposures and 
insults causing AKI, and chronic conditions and patient related factors that define how 
susceptible each patient is to develop AKI1. The type and intensity of the acute exposure is 
also of relevance. Estimating the absolute risk for AKI is challenging and attempts have 
been made to develop risk-prediction scores, but are mostly limited to patients after 
cardiac surgery160-162 or contrast medium administration163,164. ICU patients are exposed to 
numerous potential factors causing AKI, and any critical illness per se is a risk factor for 
AKI.  
 
Advanced Age25,160,165-168 and the female gender161,169 are associated with higher risk of 
developing AKI. Of chronic comorbidities chronic kidney disease (CKD)16,170,171 is one 
of the factors most clearly associated with increased AKI risk, with even a mild elevation in 
Cr172. Diabetes160,161,165,171 and cardiac dysfunction160,161,170 also increase the 
susceptibility for AKI. In cardiac surgery patients, pulmonary disease161 and liver 
disease168,173,174 are risk factors for AKI. Increasing data suggest that genetic factors175-
180 predispose some patients for AKI. CKD, sepsis, liver failure, heart failure, and 
malignancies as comorbidities increase the risk for drug induced kidney injury99.  
 
Patients with malignant conditions might have a higher risk of AKI in the ICU181. Cancer 
can cause AKI either by direct invasion to the kidneys, via septic infections or by the 
patient being subjected to nephrotoxic chemotherapeutic agents181. Tumour lysis 
syndrome (TLS) is a metabolic complication of cancer or cancer treatment that often 
leads to AKI102.  
 
Sepsis is the most common underlying cause for AKI with up to 50% of AKI cases being 
related to sepsis9,10,171,182-184. Conditions that leads to severe hypovolaemia171 or sustained 
hypotension185 predispose patients to AKI.  
 
The use of hydroxyethyl starch (HES) in ICU patients might be disadvantageous 
concerning kidney function. Three meta-analyses have concluded that the use of HES in 
critically ill patients can increase the risk for AKI186-188. HES compared to crystalloids 
increases the risk of severe AKI and initiation of RRT189. In AKI patients with severe sepsis 
HES was associated with increased need for RRT190.  
 
Albumin has been found to increase survival and decrease the incidence of AKI in 
chirrotic patients191. In ICU patients, however, no benefit from the use of albumin has been 
shown192.  The evidence to date of gelatin in relation to AKI is inconclusive193. The use of 
gelatin in ICU patients is not recommended because of lacking apparent benefit and the 
affect gelatin has on clotting194,195. 
 
Excessive fluid overload has been acknowledged as a risk factor for AKI and adverse 
outcome196. How fluid accumulation leads to AKI is not totally understood. Known 
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pathways from fluid overload to AKI are abdominal hypertension or abdominal 
compartment syndrome (ACS)197-200, and elevated venous pressure and venous congestion 
in the kidneys201,202.  
 
Major surgery167 and especially cardiac surgery203 with CPB are risk factors for AKI 
due to potential changes in haemodynamics, intravascular volume, delivery of oxygen, and 
the systemic inflammation reaction (systemic inflammatory response syndrome, SIRS) 
caused by the surgery and CPB204.  
 
Several drugs used in the ICU are known to be nephrotoxic205. Up to one quarter of severe 
AKI cases are somehow related to drug toxicity9,206. Table 3 lists potentially nephrotoxic 
drugs frequently used in the ICU.  
 
 
Table 3. Potentially nephrotoxic drugs in the intensive care unit99,207 
ACE inhibitor, ARB 
Acyclovir 
Aminoglycosides 
Amphotericin 
Contrast media 
Calcineurin inhibitors (cyclosporine, tacrolimus) 
Diuretics 
Immunoglobulins 
Metformin 
Metotrexate 
NSAID 
Peptidoglycans (Vancomycin)  
ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; NSAID, Non-
steroidal anti-inflammatory drugs 
 
 
It has been estimated that contrast media are responsible for over 10% of the new AKI 
cases in hospitalized patients208. In ICU patients the risk for contrast media-induced AKI is 
due to co-existing AKI risk factors209,210. 
 
AKI is a known complication of rhabdomyolysis in which excessive release of myoglobin 
from muscle cells due to e.g. trauma or medications damage the kidneys211,212.  
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2.6. Incidence of AKI 
 
 
The population-based incidence of AKI defined by any of the modern definitions 
(RIFLE, AKIN, KDIGO) has been evaluated in only two studies213,214 both using the RIFLE 
criteria for AKI. A retrospective study from one USA county area, representing a 
population of 124 277, reported a population-based incidence of 2900/million/year for 
ICU treated AKI213. A retrospective study from Scotland, representing a population of 523 
390, evaluated the population-based incidence of hospital-treated AKI, which was reported 
as 2147 /million /year214. 
 
Data from a large Australian database suggested that the incidence of AKI in the ICU is 
increasing215. Since the unified criteria (RIFLE) for AKI were published, several studies 
have evaluated the incidence of AKI in the ICU15,16,19,25,166-168,183,216-221. These studies are 
presented in Table 4. The incidence of AKI in these studies varied significantly from 
10.8%15 to 67.2%16. The incidence of RRT ranged from 1.0%168 to 11.9%25. All of the studies 
used the RIFLE or AKIN criteria for diagnosing and staging AKI, and in only half of them 
both Cr and UO criteria were utilized15,16,25,166,167,216,221. The observation period for 
development of AKI varied from 24 hours217 to the entire hospital stay16. Large, 
multicentre retrospective registry studies, each with over 10 000 patients, have reported 
incidences from 22%168 to 57.0%221. Altogether four15,166,167,216 prospective studies have 
been published, the largest of which included 2 164 patients15.  
 
Two studies from Finland exist. Åhlström and colleagues reported an AKI incidence of 52% 
in a prospective, single-centre study with 658 patients216. Recently in 2012, Vaara and 
colleagues performed a large nationwide database analysis with over 20 000 patients and 
reported an AKI incidence of 26.6%220. Both of the Finnish studies used the RIFLE 
classification though Vaara and colleagues without UO data.   
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2.7. Prevention and treatment of AKI 
 
No specific means to prevent or to treat of AKI are available1. The recognition of patients at 
risk before clinical symptoms are seen is therefore vital. The current guidelines for AKI 
recommend the following action for all patients at high risk for AKI: 1. discontinuing and 
avoiding nephrotoxic drugs if possible (including contrast medium), 2. optimizing 
haemodynamics and volume status, 3. starting functional haemodynamic monitoring, 4. 
monitoring of Cr and diuresis, 5. avoiding hyperglycaemia. In addition RRT and drug 
dosage changes should be considered for patients with established severe AKI1. 
2.7.1. Haemodynamics and vasoactive medication 
 
Sustained systemic hypotension leads to renal hypoperfusion and may result in AKI73. 
Normally, reduced blood flow and ischemia are well tolerated in the kidneys, however the 
autoregulation of an injured kidney is disturbed90 and a protocol-based management of 
haemodynamics in AKI prevention and treatment is recommended1 and also found 
beneficial in high-risk surgical patients185. The optimal or adequate level of blood pressure 
in patients with risk of AKI or established AKI is, however, unknown222,223.  
 
The use of vasopressors is recommended when combined with fluids in patients with 
shock. The choice between different vasopressors is not unambiguous1. Despite the use of 
dopamine in low doses with the hope of preventing AKI, data to date do not give 
rationale for this use224. Furthermore, in comparison to norepinephrine, dopamine seems 
to be associated with an increased number of adverse events225. Vasopressin has been 
suggested to have beneficial effects in AKI patients, but definitive proof of vasopressin 
reducing AKI or improving outcome is lacking226,227. 
2.7.2. Diuretics 
 
Loop diuretics are often used in patients with AKI or at risk of AKI228. Furosemide does 
not reduce mortality or the need for RRT in AKI patients, and it might have harmful effects 
on kidney function228-230. The use of furosemide is recommended only in some cases to 
treat volume overload1. 
 
2.7.3. Other medication 
 
Fenoldopam231 and atrial natriuretic peptide232 have presented some promise in 
prevention and treatment of AKI, but data from adequately powered studies233-236 have 
been unable to confirm these findings. Furthermore, existing data don’t suggest benefit 
from human insulin-like growth factor 1 (IGF-1)237-239, or erythropoietin240 to 
prevent or to treat AKI. Preliminary data from recent animal studies suggest that 
cyclosporine (a calcineurin inhibitor) might protect from AKI by blocking the 
inflammatory reaction241.  
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N-acetylcysteine might be effective in preventing contrast-induced AKI242, but in 
patients undergoing major surgery, without contrast medium exposure, no benefit in 
terms of need for RRT has been found243. Data on critically ill patients are scarce244. 
Theophylline has been shown to be renoprotective in asphyxic neonates245-247, but data 
in adults are lacking. Another adenosine receptor antagonist, rolofylline, has recently been 
studied in patients with cardiorenal syndrome, but no positive effects on survival or kidney 
function were observed248.  
 
Data suggest that a tight glycaemic control (blood glucose target 4.5 to 6 mmol/l versus 
a target of ≤ 10 mmol/l) with insulin might reduce AKI in critically ill patients, and 
especially in surgical patients249. However, in these studies, an intensive glucose control 
significantly increased the risk for severe hypoglycemia250. The current international 
guidelines recommend a blood glucose target of 6.1 – 8.3 mmol/l1. 
2.7.4. Fluids 
 
Adequate fluid therapy to restore intravascular volume and maintaining cardiac output 
and renal vascular flow in shock is recommended in the prevention of AKI251.  Estimating 
fluid responsiveness and the adequate amount of fluid resuscitation in critical illness are, 
however, very complicated198,252,253. Furthermore, based on animal models, restoring the 
systemic blood pressure with fluid therapy does not necessarily lead to improved renal 
oxygenation254,255. Excessive fluid administration results in fluid overload and fluid 
overload is a risk factor for AKI196.  
 
Though 0.9% normal saline is widely used in fluid therapy, a growing body of evidence 
suggests that the use of saline leads to hyperchloremic metabolic acidosis256,257, and can in 
addition to other adverse events, increase the incidence of kidney injury258,259. The use of 
balanced solution (e.g. Ringer’s solution, Hartmann’s solution) could be more 
advantageous in the critically ill than 0.9% saline258,260. On the basis of a large RCT, 
albumin (4%) presents no benefit in ICU patients compared to 0.9% saline192. The use of 
HES is not recommended in any ICU patients, as starches can increase the risk for AKI, 
need of RRT and mortality187,190,192.  
 
Intravenous isotonic sodium chloride (0.9% saline)261 or infusion of sodium bicarbonate262 
given before and after contrast medium has been shown to prevent from contrast media-
induced AKI. N-acetylcysteine might also offer a benefit in the prevention of contrast 
media-induced AKI for patients in high risk242,263. Although 0.9% sodium chloride was 
used in these studies, the current Finnish Guidelines for acute kidney injury recommend 
giving 1 ml/kg/h of balanced solutions 12 hours prior and 12 hours post contrast medium 
injection207 due to the disadvantages associated with excess chloride administration258,260.  
 
Mannitol is a compound used to induce osmotic stress. It is derived from sugar and 
increases urine flow, but existing data are inadequate and do not indicate a beneficial effect 
in preventing AKI264-266.    
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2.7.5. Renal replacement therapy 
 
The purpose of RRT in AKI is to: a) normalize and maintain fluid, electrolyte and acid-base 
homeostasis, b) to prevent further injury to the kidneys c) to provide time for renal 
recovery, and d) to enable the use of certain supportive treatments (e.g. antibiotics) in 
situations where other treatments have failed1. 
 
Indications for RRT are not uniform, but traditionally severe acidosis, 
hyperpotassinaemia, severe fluid overload, anuria, uremic complications, and 
hypermagnesaemia leading to loss of deep tendon reflexes have been considered as 
absolute indication for RRT. Also, a rapidly worsening kidney function, severe sepsis, and 
the overall condition of the patient should be considered1,267. A multicentre study from 
Finland described oliguria, high creatinine, acidosis and fluid accumulation as the most 
common indications for RRT initiation, though most patients had several reasons listed268. 
Not all RRT is executed for AKI, and other indications include e.g. immunomodulation in 
sepsis, removal of toxic substances, or management of dystermia267. 
 
Despite extensive research, no consensus on the most beneficial timing of RRT exists 
though it has been suggested that early would be better than late1,269.  Based on data from a 
multicentre study, RRT was generally initiated very early in the course of ICU treatment in 
Finland (41.9% on the first day)268.  
 
The modality of choice for ICU patients is typically continuous renal replacement therapy 
(CRRT), which is better tolerated in unstable patients and permits ongoing treatment for 
several days270. Intermittent treatments are usually offered later on in the course of critical 
illness when the patients are more stable. No clear difference has been shown between 
mortality in patients treated with IHD versus CRRT, however, CRRT is shown to be 
associated with haemodynamic stability271. Renal recovery might be better in patients 
treated with CRRT272.  
 
The lack of uniform guidelines on when and to whom to initiate RRT makes it a complex 
endpoint in studies and complicates the assessment of how RRT affects patient 
outcome269. AKI patients that fulfil any absolute indication for RRT are at high risk of 
dying without RRT, but on the other hand, patients with RIFLE F (Stage 3) AKI that don’t 
receive RRT have been shown to have more treatment restrictions and lower severity 
scores that patients put on RRT273.  
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2.8. Outcome of patients with AKI 
 
2.8.1. Recovery from AKI 
 
Most patients experiencing severe AKI with RRT recover completely or partially. Reported 
recovery (defined as RRT independency) rates vary from 75%274 to 95.6%275 at day 90, and 
from 90%276 to 95%277,278 at five years. However, even patients that are discharged dialysis-
free have an increased risk of both CKD with RRT dependency18 and mortality17 in the 
future. Chronic conditions such as diabetes170 and CKD are associated with nonrecovery 
from AKI279. 
2.8.2. Length-of-stay and costs for care 
 
Length-of-stay (LOS) is an outcome subjected to bias, however, many studies evaluating 
the incidence of AKI also report ICU LOS for patients with and without AKI. All of these 
studies found that AKI patients stayed significantly longer in the ICU than patients without 
AKI (Table 5)16,166,167,218,219. 
 
 
Table 5. Length of stay in the intensive care unit (ICU) for patients with and without acute kidney injury (AKI) 
Study N LOS AKI 
Median (IQR if 
available) 
LOS no AKI 
Median (IQR if 
available) 
P 
Hoste, 200616 5 383 4 (2-9) 3 (2-4) <0.001 
Medve, 2011166 459 4.5 2 <0.001 
Ostermann, 2008218 22 303 7 2 <0.001 
Piccinni, 2011167 576 7 (3-16) 3 (2-8) <0.001 
Sigurdsson, 2012219 1 026 4 (1-108) 2 (0-52) <0.001 
N, Number of patients; LOS, Length-of-stay; IQR, Interquartile range 
 
 
It is estimated that treatment of patients with AKI increases the health care cost in the 
USA by 10 billion dollars annually9,21. According to studies, AKI doubles the costs for 
hospital treatment compared to patients without AKI21,280-282.  
 
In a Finnish study from 2005, the cost of one quality adjusted life year (QALY) for AKI 
patients receiving RRT were 222 000 € / QALY for the first year282. Another RRT-patient 
study from Finland reported calculations for all costs per hospital survivor during five 
years (85 540.6 €), and the cost utility of acute RRT (270 000 €/QALY)22. No conclusive 
accepted value for one QALY has been defined, but in excess of 50 000 USD (about 40 000 
€) has been suggested283. 
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2.8.3. Health-related quality of life 
 
The health-related quality of life (HRQol) is the impact of patients’ health status on their 
quality 0f life. HRQol is a multi-dimensional concept that includes physical, mental, 
emotional and social aspects. HRQol can be measured with any of several questionnaires 
including EuroQol (EQ-5D)284, Short Form 36 (SF-36)285, the Sickness Impact Profile 
(SIP)286, the Quality of Well-being Scale (QWB)287, and Nottingham Health Profile (NHP).  
 
According to prior studies the HRQol of patients admitted to ICU is already lower than 
that of the general population before critical illness288,289. Increasing age and severity of 
illness may be associated with a poorer HRQol290. In RRT patients, existing CKD has been 
associated with a poorer HRQol after ICU treatment291. In ICU patients, an emergency 
admission, elevated Cr at admission, hypothermia, and metastatic cancer are predictors of 
poor recovery measured with the HRQol292.  
 
The HRQol of patients with AKI has been evaluated in two previous studies20,293. A recent 
prospective study concluded that the HRQol (measured with the SF-36) of patients with 
AKI at six months after ICU admission was similar to that of patients without AKI. The 
HRQol of AKI patients was also already lower compared to the general population at ICU 
admission20. Another study evaluating patients with postoperative AKI using the SF-36 
found that despite having lower scores in physical functions at six months, AKI patients 
perceived their HRQol to be better than before admission to the ICU293. 
 
Other studies reporting HRQol of AKI patients have only included RRT 
patients220,276,281,291,294-296, and have all reported impaired physical health compared to 
controls. Despite their loss of physical health, patients in these studies perceived their 
health was excellent276, and even reported that they would undergo the same treatment 
again294,295. 
 
Two studies from Finland have reported the HRQol of RRT-patients220,282. A study from 
2005 reported that the HRQol of RRT patients after ICU treatment was significantly lower 
compared to that of the age- and sex-matched general population282. The study from 2012 
concluded that the HRQol of RRT patients was equal to that of patients without RRT at six 
months220. Furthermore, in both studies, RRT patients were as content with their lives as 
the general population220,282.  
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2.8.4. Mortality 
 
Studies evaluating mortality in AKI patients are presented in Table 6. Most of the studies 
have only focused on short-term mortality (ICU, hospital)15,16,19,20,25,166,167,183,216-219. The 
lowest ICU mortality of 28.4% was from a large retrospective study from 2007183 and the 
highest ICU mortality of 54% from a small study with 183 patients297. In nine out of 
fourteen studies, hospital mortality was the chosen outcome16,19,25,166,183,216-219. Hospital 
mortality has a wide range of variation from 13.3%16 to 49.1%166.  
 
No studies have reported the 90-day mortality in AKI patients treated in the ICU and only 
three studies have reported long-term mortality at six months20,293,297. In one prospective 
study the 6-months mortality of AKI patients was 46.5%20. In two retrospective studies the 
six-month mortality for AKI patients was 58.5%297 and 38.0%293. Recently a sequentially 
matched analysis calculated, that the absolute excess mortality attributable to AKI at 90-
days was 8.6%, and that statistically 19.6% of deaths (population attributable risk, 90-day 
mortality) among ICU patients could be avoided if there was no AKI298.  
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Table 6. Studies reporting mortality for intensive care unit (ICU) patients with acute kidney injury (AKI) 
 Patients 
Study 
design 
ICU 
Mortality 
% 
Hospital 
Mortality 
% 
90-day 
Mortality 
% 
6-month 
Mortality 
% 
Abosaif, 2006297 183 R, S 54 - - 58.5 
Abelha, 2009293 1 200 R, S - - - 38.0 
Bagshaw, 2008217 120 123 R, M - 24.5 - - 
Cruz, 200715 2 164 P, M 36.3 - - - 
Hofhuis, 201320 749 P, S - - - 46.5 
Hoste, 200616 5 383 R, S - 13.3 - - 
Joannidis, 200919 14 356 R, M - 36.4 - - 
Lopes, 200825 662 R, S - 
41.3 (RIFLE) 
39.8 (AKIN) 
- - 
Medve, 2011166 459 P, M 39.3 49.1 - - 
Ostermann, 2007183 41 972 R, M 28.4 36.1 - - 
Ostermann, 2008218 22 303 R, M 31.1 40.4 - - 
Piccinni, 2011167 576 P, M 28.8 - - - 
Sigurdsson, 2012219 1 012 R, S - 37.6 - - 
Åhlström, 2006216 658 P, S - 16.7 - - 
ICU; intensive care unit, M; Multi-centre, S; Single-centre, P; Prospective, R; Retrospective, AKIN; Acute 
Kidney Injury Network Criteria, KDIGO; RIFLE; Risk, Injury, Failure, Loss, End-stage criteria,  
 
 
According to a systematic review from 2005, mortality of AKI patients has remained high 
throughout the years299. However, a study from 2007 suggested that mortality among AKI 
patients had decreased 3.4% annually from 1996 to 2005215. A major decrease in mortality 
of RRT treated patients was observed between 1988 and 2002 in a study published in 
2006300. 
 
In most studies evaluating AKI patients’ mortality, all or some RIFLE or AKIN stages have 
been independently associated with mortality15,16,19,25,166,168,183,216-219. However, even mild 
stages of AKI have been associated with increased mortality16,21,184. Advanced age9,301 and 
existing comorbidities, such as diabetes170,302 and CKD21,183,218, seemed to increase the 
mortality among AKI patients. Recent data suggest that fluid overload268,303 and HES 
use190 in AKI patients are associated with excess mortality. Also, increasing severity of 
illness and number of organ failures302, mechanical ventilation9, sepsis302 and a delayed 
ICU admission9,301 have been associated with increased mortality in AKI patients. 
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2.9. Statistical methodology 
 
2.9.1 Validity, bias and precision 
 
Validity is the extent to which the study measures what it aims to measure and how well 
the results correspond to the real world (lack of systematic errors). Internal validity 
describes how well the cohort was selected, data recorded, and the analyses performed. 
External validity refers to how well the results can be generalized to other 
populations304,305.  
 
Study bias refers to the unknown or unacknowledged errors created during the design of 
the study, data collection, sampling, procedure, or choice of problem studied. The type of 
bias can be broadly divided into selection bias, information bias and confounding bias304. 
Selection bias occurs if the process of patient inclusion presents a systematic error. 
Information bias refers to imprecisely collected or classified data. Confounding bias is an 
error in the interpretation of associations and causalities between factors and 
outcomes304,306.  
 
Precision is the lack of random error in the study results. Confidence intervals (CI) can 
be used to measure precision. The narrower the CI the more precise the result. The usual 
method is to present the 95% confidence intervals, which are based on the hypothetical 
situation that the study was to be repeated many times. More precisely, when repeated 
infinitely often with 95% CI’s, then 95% of the CIs would contain the “correct” value. More 
simply stated: with a 95% change the “correct” results lie between the interval305,306. 
Usually the CIs can be improved by increasing the sample size. In clinical studies, the 
lower 95% CI limit is often of importance representing the theoretical “minimal” value of 
the acquired result. 
2.9.2 Statistical evaluation of biomarkers 
 
Biomarkers are used to identify diseased individuals, to assess the severity of illness, to 
identify individuals at risk, to guide treatment, and to predict outcomes. To fulfil any of 
these tasks reliably, the biomarker should meet certain statistical criteria307,308.  
 
The performance of a biomarker is often described with sensitivity and specificity, which 
can be derived from a table combining the true disease state and the state indicated by the 
biomarker (Table 7 and Table 8) 
 
  41 
Table 7. Diagnostic matrix for biomarker performance 
 Disease 
Biomarker Sick Healthy 
Positive A (true positive) B (false positive) 
Negative C (false negative) D (true negative) 
modified from Ray and colleagues 2010307 
 
The sensitivity of the biomarker is the ability to identify true positives, and the specificity 
of the biomarker is the ability to identify true negatives. The positive predictive value of a 
biomarker is the likelihood that the positive result is a true positive, and the negative 
predictive value is the likelihood that a negative result is a true negative.  
 
Table 8. Calculating the quantities describing biomarker performance 
  
Sensitivity A / A + C 
Specificity D / B + D 
Positive predictive value A / A + B 
Negative predictive value D / C + D 
Positive likelihood ratio (LR+) sensitivity / (1-specificity) 
Negative likelihood ratio (LR-) (1-sensitivity) / specificity 
A, true positive; b, false positive; c, false negative; d, true negative 
 
Positive likelihood ratio (LR+) can be described as the ratio of “true positives” to “false 
positives” (sensitivity / 1 – specificity), and the negative likelihood ratio (LR-) can be 
described as the ratio of “true negatives” to “false negatives”. In general, the test in 
question is considered excellent if the LR+ is >10, good if the LR+ is 5-10, and poor if the 
LR+ is 1-5, but the clinical context should be considered when assessing relevance of 
likelihood ratios307,308.  
 
A receiver operating characteristic (ROC) curve is a graphical representation of likelihood 
ratios of individual measurements of the biomarker. Calculation of the area under the ROC 
curve (AUC) is a common way of assessing the discriminative power of a biomarker. In 
general, an AUC of > 0.9 is considered excellent, AUC of 0.75-0.9 good, and AUC of 0.5-
0.75 poor. An AUC of 0.5 is equal to a roll of a dice307. 
 
The net reclassification index (NRI) and the integrated discrimination improvement (IDI) 
are sensitive tools for detecting additional benefit of a predictive marker309-311. NRI and IDI 
can be calculated with existing meaningful risk categories or as “continuous”. In lack of 
established models for predicting the chosen outcomes, the continuous NRI can be applied 
by constructing multivariable models. When calculating the continuous NRI, each change 
(with and without the biomarker) in a probability improving the ability of the model to 
predict the true outcome, is assigned 1 and a change worsening the model is assigned -1. 
NRI is the percentage of patients whose classification improves by any amount for the 
marker in question (Figure 6). Integrated discrimination improvement (IDI) is calculated 
with the same principle using the change in the probabilities without converting them to 1 
or -1309-311. 
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Figure 6. Calculating the Net reclassification index (NRI) 
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3. AIMS OF THE STUDY 
 
 
The main aims of this study were to evaluate the nationwide incidence of AKI in Finland, 
new biomarkers for diagnosis of AKI and outcome prediction, and the effect AKI has on 
the patients’ outcome. Specific aims were: 
 
 
1. To evaluate the incidence and population-based incidence of AKI in adult patients 
treated in Finnish ICUs (I) 
 
2. To assess factors associated with development of AKI (I) 
 
3. To evaluate the ability of urine NGAL to predict AKI, RRT, and 90-day mortality (II) 
 
4. To evaluate the ability of urine IL-18 to predict AKI, RRT, and 90-day mortality 
(III) 
 
5. To evaluate the effect of AKI on the health-related quality of life (HRQol) of ICU 
patients, and to assess factors associated with a good HRQol after ICU treatment in 
patients with AKI (IV) 
 
6. To study the 90-day (I) and 6-month (IV) mortality of ICU patients with AKI.  
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4. PATIENTS AND METHODS 
 
4.1. Patients 
 
All patients in studies (I-IV) were from the prospective, observational FINNAKI study. The 
FINNAKI study was a prospective, multicentre, observational study with 17 ICUs from 
Finland participating in the study. During the five-month study period (1st of September 
2011 to 1st of February 2012) all patients admitted to these ICUs (N=5 853) were screened 
for eligibility.  
 
The FINNAKI study included all emergency ICU admissions and electively admitted 
patients, whose stay exceeded 24 hours.  The study excluded:  
1. Patients under 18 years of age  
2. Re-admitted patients who received RRT during their previous admission  
3. Elective ICU patients treated for less than 24 hours if discharged alive  
4. Patients on chronic dialysis 
5. Organ donors  
6. Patients with no permanent residency in Finland or insufficient language skills  
7. Patients transferred from another ICU if they had already participated in the 
study for 5 days  
8. Intermediate care patients.  
 
Study I included all FINNAKI study patients (N=2901). For Study II and Study III, a 
set of FINNAKI patients were randomly chosen from those with available urine samples. 
Study II included a total of 1042 patients from 15 different study centres with at least one 
urine NGAL sample analysed from the first 24 hours of ICU admission. Study III 
included 1439 patients from 17 different study centres with a urine IL-18 sample analysed 
from ICU admission. For Study IV, study centres that achieved a follow up rate of over 
70% concerning the six-month EQ-5D were chosen. Study IV included altogether 1568 
patients from 10 different study centres. Table 9 presents the numbers of patients in each 
study and Figure 7 illustrates a flow chart of studies I-IV.  
 
 
Table 9. Numbers of patients in studies I-IV 
Study Number of patients Criteria for selecting patients 
I 2 901 All patients recruited to FINNAKI 
II 1 042 A random set of patients with urine samples from the first 24 hours 
after ICU admission 
III 1 439 A random set of patients with urine samples available from the time 
of ICU admission 
IV 1 568 All patients from study centres with >70% EQ-5D follow-up rate at 
six months 
EQ-5D, EuroQol Health-related quality of life questionnaire; ICU, Intensive Care Unit 
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In case of multiple admissions, the admission with the patient’s highest KDIGO stage was 
chosen in all studies (I-IV). For patients that were transferred between two study ICUs 
during the first five ICU days, the data from these admissions were combined. Patient 
characteristics for all patients in studies I-IV are presented in Table 10.  
 
The Ethics Committee of the Department of Surgery in Helsinki University Hospital gave 
approval for the FINNAKI study data collection and for the use of a deferred consent 
policy. The Finnish National Institute of Health gave approval for data collection from 
medical records of deceased patients lacking a written consent. For all other study patients 
a written, informed consent was obtained from the patient or proxy.  
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Figure 7. Flow chart of studies I-IV. RRT, Renal replacement therapy; AKI, Acute kidney injury; EQ-5D, 
EuroQol Health-related quality of life questionnaire.  
  47 
 
Table 10.  Characteristics of patients in studies I-IV 
 Study I 
N=2901 
Study II 
N=1042 
Study III 
N=1439 
Study IV 
N=1568 
Age, years 64 (51-74) 63 (51-73) 63 (50-73) 65 (53-74) 
Gender, male 1846 (63.6) 673 (64.6) 920 (63.9) 1015 (64.7) 
Baseline Cr (µmol/l) 76 (61-93) 77 (62-92) 74 (60-91) 78 (63-95) 
SAPS II score (points) 37 (28-50) 36 (27-48) 36 (27-47) 36 (27-49) 
SOFA score (first 24 hours, points) 7 (4-9) 7 (4-9) 7 (4-9) 7 (5-10) 
Emergency admission 2544 (87.7) 912 (87.5) 1286 (90.1) 1287 (82.1) 
Surgical admission 1010 (34.8) 362 (34.7) 485 (33.7) 618 (39.4) 
DIAGNOSTIC GROUP (APACHE III) 
Cardiovascular, operative 438 (15.1) 160 (15.4) 182 (12.6) 355 (22.6) 
Cardiovascular, non-operative 390 (13.4) 154 (14.8) 189 (13.1) 231 (14.7) 
Respiratory tract, non-operative 353 (12.2) 121 (11.6) 178 (12.4) 184 (11.7) 
Metabolic 262 (9.0) 94 (9.0) 139 (9.7) 133 (8.5) 
Neurological, non-operative 255 (8.8) 76 (7.3) 133 (9.2) 85 (5.4) 
Gastrointestinal tract, operative 253 (8.7) 95 (9.1) 135 (9.4) 152 (9.7) 
Gastrointestinal tract, non-operative 189 (6.5) 59 (5.7) 92 (6.4) 92 (5.9) 
Trauma 186 (6.4) 63 (6.0) 99 (6.8) 70 (4.5) 
Sepsis 182 (6.3) 67 (6.4) 89 (6.2) 99 (6.3) 
Other (<5% each) 393 (13.5) 153 (14.7) 203 (14.1) 167 (10.7) 
Values are presented as numbers (percentages) or median (interquartile range, IQR); Cr, creatinine; SAPS 
II, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assesssment; APACHE II, Acute 
Physiology and Chronic Health Evaluation 
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4.2. Study design 
 
4.2.1. Study I 
 
Study I described the whole FINNAKI study cohort. The aims of this study were to report 
the incidence, population-based incidence, risk factors, and outcome (90-day mortality) of 
patients with AKI in a consecutive, nationwide cohort of mixed critically ill adult patients.  
 
4.2.2. Study II 
 
This study evaluated the ability of urine NGAL to predict AKI, RRT, and 90-day mortality 
in critically ill adult patients. NGAL was analysed at ICU admission, at 12h and at 24 h if 
available. The highest NGAL was then selected for statistical analyses for each patient. 
Sensitivity analyses were performed first for all and then in subgroups excluding: 1) septic 
patients, 2) patients who had AKI or received RRT on admission day, and 3) patients 
lacking a true baseline Cr value. 
 
4.2.3. Study III 
 
This study assessed urine IL-18 as a diagnostic marker for AKI, and as an outcome marker 
predicting RRT, or 90-day mortality. IL-18 at ICU admission, and at 24 h, was analysed 
and the highest value was chosen for statistical analyses. The association of the change in 
IL-18 from admission to 24 h with AKI, RRT, and 90-day mortality was also analysed. The 
predictive powers of urine IL-18 and NGAL were also compared in patients with both 
biomarkers available.  
 
Study III was originally designed to also evaluate the prognostic power of kidney injury 
molecule 1 (KIM-1) in the same patient population as IL-18, but the data concerning KIM-1 
were excluded after analysis due to implausible results.   
4.2.4. Study IV 
 
This study described the long-term outcome of AKI patients assessed by the patients’ 
health-related quality of life, and by their six-months mortality. The HRQol of the study 
patients was measured at admission and at six months with the EQ-5D questionnaire, and 
compared to the age- and sex-matched general Finnish population. Also, factors associated 
with a good quality of life after ICU treatment were assessed.  
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4.3. Data collection 
 
 
Study data was collected from the Finnish Intensive Care Consortium’s (FICC) prospective 
database and with a study specific case report form (CRF). Data were recorded for five 
days in the ICU for each patient. Collection was terminated early if the patient was 
discharged before day five.     
 
All of the 17 study ICUs belong to the Finnish Intensive Care Consortium (FICC). The FICC 
database was originally established in 1994 for benchmarking purposes, has since 
expanded, and is currently handled by Tieto Healthcare & Welfare Ltd. The database 
routinely records patient demographics, APACHE III admission diagnosis, International 
Classification of Diseases 10th revision (ICD-10) diagnosis, ICU severity scores (SOFA, 
SAPS II, TISS), length-of-stay, and ICU- and hospital mortality. In addition the database 
records, an extensive set of physiologic data, most of which are automatically transferred 
via the clinical information systems from patient monitors, ventilators, and laboratory 
systems. Some data, such as the HRQol by EQ-5D scores and vital status at hospital 
discharge, are entered manually into the database. Before being saved into the central 
database, local processes by automated filters and trained personnel validate the data. The 
completeness of the data is routinely monitored and has been found to be good312. Some 
variables (e.g. hourly urine output) were added to the database for the purpose of this 
study. An automated calculator built into the database did calculations for the severity of 
the kidney injury with regard to UO.  
 
A study specific CRF was developed to augment the data from the database. The ICU 
physician and/or nurse filled this CRF at admission, daily for five days, and at ICU 
discharge. Data collected with the CRF comprised of chronic and present health status, 
medications, information on possible risk factors for AKI, evaluation of severe sepsis, 
disseminated intravascular coagulation (DIC), other organ dysfunction, fluid balance, and 
RRT. The CRF variables were altogether 54% of the whole dataset. The reliability of this 
CRF data was monitored in eight randomly chosen study centres with a structured 
monitoring plan.  
 
4.4. Population-based calculations 
 
To perform calculations of the population-based incidence, the number of adults in the 
study area (participating hospital districts) in December 2011 was obtained from Statistics 
Finland. The Finnish Registry for Kidney disease provided the number of adults on chronic 
RRT. This number (N= 1 527) was subtracted from the whole population resulting in a 
reference population of 3 671 143 adults, which corresponds to 85.1% of the whole Finnish 
adult population.  
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4.5. Laboratory sample collection 
 
Urine samples were collected from the study patients at ICU admission, 12 h, and 24 h. 
Urine was collected with a sterile technique from Foley catheters. The admission sample 
was taken immediately after admission or at 2 hours at the latest. The samples were 
aliquoted and either stored first temporarily at -20 °C, or immediately at -80 °C, where 
they were stored until assayed.  The longest storage time at -80 °C was six months.  
 
4.6. Laboratory assays 
 
4.6.1. Neutrophil gelatine-associated lipocalin (II) 
 
Urine NGAL was analysed with a commercially available enzyme linked immunosorbent 
assay (ELISA) following manufacturer’s instructions (BioPorto® Gentofte, Denmark). The 
analyst was blinded to patient information.  
 
The samples were diluted 1/50 and the validated ELISA method313 had a measurement 
range of 10 to 1000 ng/ml with the chosen dilution. Out of range values were registered as 
the highest of lowest value (10 or 1000 ng/ml). The chosen kit shows good intra-assay 
precision (median coefficient of variation, CV% <5%), and inter-assay precision (CV% 
<10%). For the statistical analyses the highest NGAL of the first 24 hours was used.  
 
4.6.2. Interleukin 18 (III) 
 
Urine IL-18 was analysed with a commercially available enzyme linked immunosorbent 
assay ELISA kit (Cusabio Biotech® Wuhan, China), according to the manufacturer’s 
instructions by an analyst blinded to patient information.  
 
The samples were concentrated 2 fold, and with this the detection range of this method is 
3.9 – 250 pg/ml. Out of range values were registered as the highest and lowest value. The 
IL-18 kit shows good intra-assay and inter-assay precision for samples tested from urine 
(CV% <10%). The highest IL-18 of the first 24 hours and the change in IL-18 from 
admission until 24 hours were used for statistical analyses. 
 
Urine kidney injury molecule 1 (KIM-1) was also analysed from the same patient 
population with an immunosorbent ELISA (ALPCO® Diagnostics, Salem, USA) assay. Due 
to unknown reasons, over 90% of the results were below the detection limit.  These data 
were then discarded because of an evident problem in some stage of the analysis (Nisula et 
al, unpublished data).  
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4.7. Definitions 
4.7.1. Acute kidney injury 
 
In all studies (I-IV), AKI was defined with the Kidney Disease: Improving Global 
Outcomes (KDIGO) criteria1 with both daily Cr measurements and hourly urine output and 
a continuous moving baseline for both. The FINNAKI study was originally designed with 
the AKIN3 criteria supplemented with a historical baseline Cr. The KDIGO criteria were 
published in 2012 concurrently with the study data collection, and when the data were 
analysed, the AKI staging in study population was calculated using the KDIGO criteria. 
This resulted in identical classification of the study patients. In all studies (I-IV) the 
baseline serum Cr was defined as the latest measurement from the previous year, however 
excluding the previous week. For patients lacking a baseline, the Modification of Diet in 
Renal Disease (MDRD) equation39, assuming a glomerular filtration rate of 75 
ml/min/1.73 m2, was used as recommended by the ADQI29. The highest AKI stage for each 
patient was used in the incidence calculations. The patients’ AKI and RRT status was 
screened for five days in the ICU (I, IV). For the biomarker studies (II, III), in evaluating 
samples from the first 24 hours of ICU admission, the screening period of AKI and RRT 
was limited to three days.  
4.7.2. Sepsis and DIC 
 
Evaluation of sepsis and severe sepsis, and DIC, were done daily using the American 
College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM)314 and 
International Society on Thrombosis and Haemostasis (ISTH) criteria315. 
4.7.3. Risk Factors for AKI 
 
In study I the potential risk factors for AKI were defined as follows: hypotension: systolic 
blood pressure < 90 mmHg for 1 hour, rhabdomyolysis: creatinine kinase (CK) > 5000 U/l 
or myoglobin > 5000 µg/l, hypovolaemia: hypovolaemia by clinicans´ judgement, 
resuscitation: a haemodynamic collapse requiring chest compressions, defibrillation or 
administration of adrenalin, low cardiac output: inadequate systolic function + 
hypotension + signs of tissue hypoxia, massive transfusion: transfusion of more than 10 
red blood cell units in 48 hours. Data on hypotension, hypovolaemia, low cardiac output, 
and massive transfusion were only recorded prior to ICU admission. Colloids before ICU 
admission included HES and gelatin, and during the ICU stay also albumin.  
4.7.4. Renal replacement therapy 
 
RRT was defined by either continuous or intermittent treatment initiated in the ICU 
during five days in study I and IV, and during three days in studies II and III. No specific 
indications for initiation of RRT were defined for this was an observational study and all 
study centres followed their routine guidance.   
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4.8. Outcome measures  
 
4.8.1. Health-related quality of life (IV) 
 
The EuroQol (EQ-5D) quality of life questionnaire was used to assess the health-related 
quality of life of the study patients a) at ICU admission (HRQol prior to critical illness) and 
b) at six-months after ICU admission. Collection of this data is a part of the FICC database 
routines. The ICU nurse presented the questions to the patient or proxy at the first eligible 
time after admission. The follow-up at six-months was carried out by mail or telephone. 
EQ-5D data obtained from proxies have been shown to be reliable316,317.   
 
The EQ-5D284 is a validated tool in measuring HRQol in critically ill patients318,319. It has 
five dimensions (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) that are all assessed on a scale from 1 to 3. The answers are combined 
to an index score (range from 0 to 1) with population-based weight coefficients. The index 
scores can be used to compare different populations. As a part of the questionnaire, a 
visual analogue scale describes the respondent’s self-rated health on a scale from 0 to 100. 
Based on previous data, a significant change in the EQ-5D index is 0.08, and for the VAS 
score 7320,321.  
 
4.8.2. Mortality (I-IV) 
 
The 90-day and 180-day (6 months) mortality were obtained from the Finnish Population 
Register Centre (http://www.vrk.fi) using the study patients’ social security numbers. 
 
 
4.9. Statistical methods 
 
Nominal data were presented as numbers (percentages). Continuous data (as not normally 
distributed) were presented as medians with interquartile range (IQR, 25th – 75th 
percentiles). Categorical variables were compared with the Chi-square test or the Fisher’s 
exact test when appropriate, and continuous variables with the Mann-Whitney U-test. The 
Wilcoxon signed rank test was used to compare repeated measurements of EQ-5D (IV). 
Kaplan-Meyer survival curves were built for AKI patients (I). A backwards-conditional 
stepwise logistic regression analysis was performed to calculate odds ratios for 
independent association to AKI and 90-day mortality (I) 
 
To evaluate the properties of biomarkers (II, III), receiver operating characteristics curves 
(ROC) were constructed and the areas under curves (AUC) with 95% confidence intervals 
were calculated. Best cut-off values with 95% CIs (II) were identified with the Youden 
index and the sensitivities, specificities, and positive likelihood ratios (LR+) were 
calculated. To evaluate the additive predictive power of the biomarkers, the continuous net 
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reclassification improvement (NRI) and integrated discrimination improvement (IDI)309-
311 were calculated. For this purpose, multivariable predictive models (enter model) for 
each endpoint were constructed by inserting variables proven significant in a univariable 
model. The model was then tested with and without the biomarker. Probabilities from 
these models were used to calculate the continuous NRI and IDI.  
 
The sample size calculations of the FINNAKI study were based on targeting clinically 
significant 95% CIs of ± 2.0% for the incidence of AKI. In studies II and III sample size 
calculation were based on the 95% CI limits of AUC as previously described322 targetting 
sample sizes providing clinically relevant CIs less than ± 0.05 (<0.1) for all endpoints using 
incidences for AKI, RRT and 90-day mortality from the whole study cohort.  
 
A P-value of <0.05 was considered significant. As an exception, when selecting variables to 
the predictive models (III, IV) on the basis of univariable models, a P-value of 0.2 was 
considered adequate. 
 
The Youden index and cutoff points (II) were calculated with MedCalc version 12.7.2 
(MedCalc Software, Belgium) and all other analyses with SPSS version 19 - 21 (SPSS, 
Chicago, Ill., USA) 
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5. RESULTS 
 
5.1. Incidence of AKI (I) 
 
The total number of patients in each study centre varied between 59 and 419 (I). The 
incidence of AKI ranged from 20.7% to 53.5% in different study centres (Table 11). The 
incidence of AKI in the whole study population was 1141/2901 (39.3%, 95% CI 37.5 - 
41.1%). KDIGO stage 1 AKI was present in 499 (17.2%, 95% CI 15.8 - 18.6%) patients, stage 
2 in 232 (8.0%, 95% CI 7.0 – 9.0%) patients, and stage 3 in 410 (14.1%, 95% CI 12.8 – 
15.4%) patients. RRT was initiated during the first five ICU treatment days in 272/2901 
patients (9.4%, 95% CI 8.3% - 10.5%).  
 
The population-based incidence of AKI in adult ICU patients, calculated from the 
number of adult inhabitants in the area of the participating hospital districts, was 746 
(95% CI 717 - 774) per million adults per year.  
 
 
Table 11. The numbers (percentages) of patients with acute kidney injury (AKI) in individual FINNAKI study 
sites (Nisula et al, unpublished results) 
Site AKI patients 
N (%) 
 
1 123/307 (40.1) UH 
2 153/286 (53.5) UH 
3 85/193 (44.0) UH, CS 
4 121/419 (28.9) UH 
5 107/314 (34.1) UH 
6 19/92 (20.7)  
7 46/141 (32.6)  
8 53/108 (49.1)  
9 61/165 (37.0)  
10 36/101 (35.6)  
11 61/120 (50.8)  
12 37/97 (38.1)  
13 51/113 (45.1)  
14 91/223 (40.8) UH 
15 28/63 (44.4)  
16 23/59 (39.0)  
17 46/100 (46.0)  
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); UH; University 
Hospital; CS, Cardiac Surgery  
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The total number of AKI patients, AKI patients stratified into different KDIGO stages and 
numbers of RRT patients in studies I-IV are presented in Table 12.  
 
 
Table 12. Incidences of acute kidney injury (AKI) and renal replacement therapy (RRT) and numbers of 
patients in different KDIGO stages in studies I-IV 
Study (N) AKI Stage I Stage II Stage III RRT 
I (2901) 1141 (39.3) 499 (17.2) 232 (8.0) 410 (14.1) 272 (9.4) 
II* (1042) 379 (36.4) 168 (16.1) 81 (7.8) 130 (12.5) 83 (8.0) 
III* (1439) 497 (34.5) 213 (14.8) 113 (7.9) 171 (11.9) 96 (6.7) 
IV (1568) 635 (40.5) 280 (17.9) 119 (7.6) 236 (15.1) 162 (10.3) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); RRT, Renal 
Replacement Therapy, KDIGO, Kidney Disease: Improving Global Outcomes Criteria *For studies II and III 
observation period for AKI and RRT was 3 days. Numbers are presented as count (percentage) 
 
5.2. Risk factors for AKI (I) 
 
In study I, patients that developed AKI were significantly older (median 66 versus 62 
years), more often male (66.2% versus 62.0%), and had a higher baseline creatinine value 
than patients without AKI (median 78.0 µmol/l versus 73.0 µmol/l). Patients with AKI 
were generally more ill judged by SAPS (43 versus 33 points) and SOFA scores (first 24 
hours median 9 versus 6), they required mechanical ventilation (74.8% versus 65.9%) and 
vasoactive treatment (78.1% versus 53.4%) more often, and had a higher lactate level 
(median 2.7 mmol/l versus 1.9 mmol/l) during the first 24 hours of their ICU stay. 
Emergency surgery prior to the ICU admission was significantly more common in AKI 
patients (24.5% versus 20.8%), but the type of admission (emergency/non-emergency, 
post-operative/non-operative) was not of significance.  
 
As shown by Table 13, hypertension, arteriosclerosis, diabetes, systolic heart failure, and 
chronic kidney disease were significantly more common in patients with AKI than in 
patients without AKI. AKI patients had ACE-inhibitors or ARBs, NSAIDs, diuretics, 
metformin, statins, or corticosteroids more often as permanent medications than patients 
without AKI. Table 13 presents chronic co-morbidities and medications in patients with 
and without AKI.  
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Table 13. Co-morbidities and medication in patients with and without acute kidney injury (AKI). 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); ACE-inhibitor, 
angiotensin convertase enzyme-inhibitor; ARB, angiotensin II receptor blocker; NSAID, non-steroid anti-
inflammatory drug. 
 
Acute events that were studied as possible risk factors for AKI are presented in Table 14. 
According to the results, severe sepsis, DIC, resuscitation, and administration of ACE-
inhibitors or ARBs were significantly more frequent in patients who developed AKI both 
prior to ICU admission and when including time in the ICU before the development of 
AKI.  
 
Rhabdomyolysis and emergency surgery were more common among AKI patients before 
ICU, but when including the ICU admission, there was no longer a significant difference. 
Concerning hypotension, hypovolaemia, low cardiac output, and massive transfusion data 
were only available prior to ICU, but all of these were significantly more common in 
patients that developed AKI. Peptidoglycan antibiotics were given in equal amounts to 
patients that did or did not develop AKI.  
 
Contrast medium was more frequently given to patients that didn’t develop AKI both 
before ICU and during the admission. Almost 40% of the patients that developed AKI 
received diuretics prior to their ICU admission, which was significantly more than to 
patients that didn’t develop AKI. However, this was reversed when including the time in 
the ICU into the analysis. NSAIDs were given equally to patients that later on developed 
AKI and to those that didn’t before ICU but less AKI patients received NSAIDs in the ICU. 
Also, patients that developed AKI received significantly more colloids prior to their ICU 
admission, but that difference no longer existed after including the time in the ICU.  
 Data 
available 
No AKI 
(N=1760) 
N (%) 
AKI 
(N=1141) 
 N (%) 
P 
Co-morbidity     
Chronic obstructive pulmonary disease 2883 148 (8.4) 116 (10.3) 0.058 
Hypertension 2885 749 (42.8) 630 (55.5) <0.001 
Arteriosclerosis 2870 194 (11.1) 186 (16.5) <0.001 
Diabetes 2897 345 (19.6) 292 (26.6) <0.001 
Systolic heart failure 2874 176 (10.1) 159 (14.1) 0.001 
Chronic kidney disease 2889 67 (3.8) 122 (10.8) <0.001 
Medication     
ACE-inhibitor or ARB 2839 555 (32.3) 481 (43.0) <0.001 
NSAID 2785 129 (7.6) 113 (10.3) 0.01 
Diuretic 2847 398 (23.1) 410 (36.4) <0.001 
Aspirin 2845 449 (26.0) 334 (29.8) 0.016 
Metformin 2854 188 (10.9) 161 (14.3) 0.004 
Statin 2856 471 (27.2) 389 (34.5) <0.001 
Corticosteroids 2864 118 (6.8) 104 (9.2) 0.011 
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Table 14. Events preceding acute kidney injury (AKI). 
 NO AKI 
(N=1760) 
N / total / (%) 
AKI 
(N=1141) 
N / total / (%) 
P 
Events before ICU admission 
Severe sepsis 299 /1760 (17.0) 367/1141 (32.2) <0.001 
DIC 16 /1750 (0.9) 41/1135 (3.6) <0.001 
Hypotension 303/1744 (17.4) 395/1117 (35.4) <0.001 
Rhabdomyolysis 37/1756 (2.1) 40/1138 (3.5) 0.015 
Hypovolaemia 404/1754 (23.0) 467/1127 (41.4) <0.001 
Resuscitation 169/1757 (9.6) 150/1138 (13.2) 0.002 
Low cardiac output 56/1758 (3.2) 81/1138 (7.1) <0.001 
Massive transfusion 46/1760 (2.6) 47/1141 (4.1) 0.017 
Emergency surgery 366/1758 (20.8) 279/1139 (24.5) 0.012 
Radiocontrast dye 454/1751 (25.9) 247/1134 (21.8) 0.006 
Peptidoglycan antibiotics 131/1757 (7.5) 102/1136 (9.0) 0.081 
ACE-inhibitor or ARB 388/1733 (22.4) 326/1108 (29.4) <0.001 
NSAID 152/1684 (9.0) 109/1084 (10.1) 0.201 
Diuretics 428/1713 (25.0) 436/1104 (39.5) <0.001 
Colloids  439/1634 (26.9) 409/1086 (37.7) <0.001 
Events before day 5 (including 48-hours preceding ICU admission) 
Severe sepsis 365/1760 (20.7) 388/1141 (34.0) <0.001 
DIC 29/1759 (1.6) 52/1138 (4.6) <0.001 
Rhabdomyolysis 56/1760 (3.2) 41/1139 (3.6) 0.307 
Resuscitation 194/1760 (11.0) 155/1138 (13.6) 0.021 
Emergency surgery 504/1758 (28.7) 323/1139 (28.4) 0.445 
Radiocontrast dye 550/1759 (31.3) 273/1137 (24.0) <0.001 
Peptidoglycan antibiotics 184/1760 (10.5) 119/1139 (10.4) 0.524 
ACE-inhibitor or ARB 468/1760 (26.6) 340/1127 (30.2) 0.021 
NSAID 226/1757 (12.9) 120/1125 (10.7) 0.043 
Diuretics 1063/1760 (60.4) 597/1122 (53.2) <0.001 
Colloids  774/1760 (44.0) 513/1114 (46.1) 0.147 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); ACE-inhibitor, 
angiotensin convertase enzyme-inhibitor; ARB, angiotensin II receptor blocker; DIC, disseminated 
intravascular coagulation; Colloid, HES or gelatin (including albumin in the ICU); Hypotension, systolic blood 
pressure < 90 mmHg for 1 hour before ICU admission; Hypovolemia, by clinicans´ judgement before ICU 
admission; Low Cardiac Output, inadequate systolic function + hypotension + signs of tissue hypoxia before 
ICU admission; Massive transfusion, transfusion of more than 10 red blood cell units in 48 hours before ICU 
admission; NSAID, non-steroid anti-inflammatory drug; Rhabdomyolysis, CK > 5000 U/l or myoglobin > 5000 
µg/l; Resuscitation, haemodynamic collapse requiring CPR, defibrillation or administration of adrenalin;. 
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In this study population, based on a logistic regression analysis, several conditions were 
independently associated with the development of AKI, including: 1) hypovolaemia prior to 
ICU admission, 2) administration of diuretics prior to ICU admission, 3) administration of 
colloids prior to ICU admission, and 4) chronic kidney disease Table 15 shows the model-
based odds ratios (OR) for these variables. 
 
Table 15. Factors independently associated with acute kidney injury (AKI)  
Variable Odds ratio 95% CI 
Pre-ICU hypovolaemia 2.20 1.85 – 2.62 
Pre-ICU diuretics 1.68 1.41 – 2.00 
Pre-ICU colloids 1.35 1.13 – 1.61 
Chronic kidney disease 2.64 1.88 – 3.71 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); 
Hypovolaemia, by clinicians’ judgment; Colloids, gelatin in 52% of patients, starch in 40% of patients, and 
both in 8% of patients 
 
5.3. Novel biomarkers for AKI 
5.3.1. Neutrophil gelatinase-associated lipocalin (II) 
 
At least one urine NGAL sample was analysed from altogether 1042 patients. The highest 
uNGAL value was below the detection limit in 107 (10.3%) patients and exceeded the upper 
limit in 184 (17.7%) patients. The numbers (percentages) of samples analysed at each time 
point of study patients still in the ICU, were 965/1042 (93%) at 0 h, 669/1006 (67%) at 12 
h, and 817/848 (96%) at 24 h. In 56% of the patients, the highest uNGAL value was from 
the admission sample.  
 
Receiver operating characteristic (ROC) curves for urine NGAL in the prediction of AKI, 
RRT and 90-day mortality are presented as Figure 8. The performance of the highest urine 
NGAL of the first 24 hours of ICU admission in the prediction of AKI, RRT, and 90-day 
mortality is presented in Table 16.  
 
A sensitivity analysis excluding events on day 1, leaving 201 AKI patients and 45 RRT 
patients, resulted in AUCs (with 95% CI) of 0.668 (0.624 – 0.712) for NGAL in prediction 
of AKI, and 0.857 (0.805 – 0.909) in prediction of RRT. Table 17 presents the sensitivity 
analyses, excluding septic patients, events on day 1, and patients without a known baseline 
creatinine.  
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Figure 8. Receiver operating characteristics curves (ROC AUC with 95% Confidence Interval) for urine 
NGAL in prediction of a) acute kidney injury, b) renal replacement therapy, and c) 90-day mortality 
 
 
Adding NGAL to the predictive models constructed for AKI, RRT, and 90-day mortality 
changed the probability–based ROC AUCs (95% CI) from 0.705 (0.672-0.738) to 0.752 
(0.721-0.783) concerning AKI, from 0.938 (0.910-0.966) to 0.945 (0.918-0.972) 
concerning RRT, and from 0.821 (0.791-0.852) to 0.823 (0.793-0.854) concerning 90-day 
mortality.  
 
 
 
Table 16. AUC’s, sensitivities, specificities, best cut-off values, positive likelihood ratios, NRIs, and IDIs for 
urine NGAL (24-hour highest value) regarding prediction of acute kidney injury (AKI), renal replacement 
therapy (RRT), and 90-day mortality 
 
AKI 
(N=379) 
RRT 
(N=83) 
90-day mortality 
(N=225) 
AUC (95% CI) 0.733 (0.701 – 0.765) 0.839 (0.797 – 0.880) 0.634 (0.593 – 0.675) 
Sensitivity 0.665 0.831 0.542 
Specificity 0.704 0.785 0.681 
Cut-off ng/ml (95% CI) 157 (73 – 225) 449 (219 – 538) 229 (76 – 988) 
LR+ 2.24 (1.95 – 2.57) 3.81 (3.26 – 4.47) 1.70 (1.45 – 1.98) 
NRI 56.9% 56.3% 15.3% 
IDI 0.071 0.022 <0.001 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); AUC, Area 
Under the Curve; 95% CI, 95% Confidence Interval; LR+, Positive likelihood Ratio, NRI, Net Reclassification 
Index; IDI, Integrated Discrimination Improvement; RRT, Renal Replacement Therapy 
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Table 17. Sensitivity analyses for urine NGAL (24-hour highest value) regarding prediction of acute kidney 
injury (AKI), renal replacement therapy (RRT), and 90-day mortality.  
 AUC (95% CI) 
Non-septic patients (N= 554)  
 AKI (N=162) 0.702 (0.654 – 0.750) 
 RRT (N=37) 0.863 (0.792 – 0.934) 
90-day mortality (N=88) 0.600 (0.534 – 0.665) 
Events on day 1 excluded  
AKI (N=201) 0.668 (0.624 – 0.712) 
RRT (N=45) 0.857 (0.805 – 0.909) 
Patients with known baseline Cr (N=665)  
AKI (N=253) 0.732 (0.692 – 0.771) 
RRT (N=53) 0.847 (0.803 – 0.890) 
90-mortality (N=166) 0.654 (0.607 – 0.700) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); RRT, Renal 
Replacement Therapy; 95% CI, confidence interval; AUC, area under receiver characteristics curve 
5.3.2. Interleukin 18 (III) 
 
An admission IL-18 sample was analysed from 1439 patients, of which 1080 patients also 
had the 24 hours sample available. The 229 of the 497 AKI patients who had AKI on the 
first ICU day were excluded from the analyses concerning AKI as on endpoint, and 
similarly 47 of the 96 RRT patients were excluded from the analyses concerning RRT. 
Figure 9 illustrates the ROC curves for IL-18 in the prediction of AKI, RRT, and 90-day 
mortality.  
 
 
 
Figure 9. Receiver operating characteristics curves (ROC AUC with 95% Confidence Interval) for urine IL-18 
in prediction of a) acute kidney injury, b) renal replacement therapy, and c) 90-day mortality 
 
Table 18 presents AUC (with 95% CI), sensitivities, specificities, best cut-off values, and 
positive likelihood ratios (LR+) for the highest IL-18 during the first 24 hours in prediction 
of AKI, RRT, and 90-day mortality. Sensitivity analyses were performed to exclude the bias 
from septic patients and estimated baseline creatinine. The results of these sensitivity 
analyses are presented in Table 19.  
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Table 18. AUC’s, sensitivities, specificities, best cut-off values, and positive likelihood ratios for urine IL-18 
(24-hour highest value) regarding prediction of acute kidney injury (AKI), renal replacement therapy (RRT) 
and 90-day mortality 
 
AKI 
(N=268) 
RRT 
(N=49) 
90-day mortality 
(N=289) 
AUC (95% CI) 0.586 (0.546-0.627) 0.655 (0.572-0.739) 0.536 (0.497-0.574) 
Sensitivity 0.384 0.551 0.398 
Specificity 0.778 0.739 0.683 
Cut-off ng/ml (95% CI) 65 65 44 
LR+ 1.72 (1.41-2.08) 2.04 (1.54-2.69) 1.25 (1.06-1.47) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); AUC, Area 
Under the Curve; 95% CI, 95% Confidence Interval; LR+, Positive likelihood Ratio, RRT, Renal Replacement 
Therapy 
 
In the 1080 patients with both IL-18 samples available, the change in IL-18 from 
admission to 24 h predicted new AKI with an AUC (95% CI) of 0.557 (0.514 - 0.601). For 
prediction of RRT, the AUC (95% CI) was 0.531 (0.428 - 0.633), and the change in IL-18 
produced an AUC (95% CI) of 0.489 (0.447 - 0.532) for 90-day mortality. Figure 10 shows 
the temporal changes in IL-18 from admission to 24h stratified by presence of AKI during 
the first three ICU days.  
 
 
 
 
Figure 10. Boxplot of urine IL-18 on admission and 24 hours stratified by the presence of AKI during the first 
three ICU days in patients with both samples available (N=1080) 
 
  62 
The multivariable model constructed to predict AKI in this population produced AUCs 
(95% CI) of 0.693 (0.649-0.737) without and 0.697 (0.653-0.741) with IL-18. In this 
model, chronic kidney disease, SAPS II (without age and renal points), SOFA (without 
renal points), highest lactate of day 1, severe sepsis, and IL-18 were independently 
associated with development of AKI. The model for 90-day mortality produced AUCs (95% 
CI) of 0.824 (0.795-0.854) without, and 0.824 (0.795-0.854) with, IL-18. Age, liver 
disease, SAPS II (without age and renal points), acute liver failure, and AKI were 
independently associated with 90-day mortality. 
 
Table 19. Sensitivity analyses for urine IL-18 (24-hour highest value) regarding prediction of acute kidney 
injury (AKI), renal replacement therapy (RRT), and 90-day mortality.  
 AUC (95% CI) 
Non-septic patients (N= 749)  
 New AKI (N=116) 0.563 (0.502-0.624) 
 RRT (N=16) 0.780 (0.668-0.893) 
90-day mortality (N=98) 0.534 (0.472-0.597) 
Patients with known baseline Cr (N=917)  
New AKI (N=174) 0.570 (0.519-0.620) 
RRT (N=32) 0.643 (0.539-0.748) 
90-mortality (N=212) 0.552 (0.508-0.597) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); RRT, Renal 
replacement Therapy; 95% CI, confidence interval; AUC, area under receiver characteristics curve 
 
5.3.3. IL-18 versus NGAL (III) 
 
For 855 patients both the admission urine IL-18 and NGAL were available. Figure 11 shows 
the comparing ROC curves of IL-18 and NGAL for the chosen outcomes and Table 20 lists 
the corresponding AUCs (95% CI) of NGAL, IL-18, and IL-18 * NGAL (IL-18 times NGAL) 
in prediction of AKI, RRT, and 90-day mortality.   
 
 
 
 
Figure 11. Receiver operating characteristic (ROC) curves for NGAL regarding prediction of a) acute kidney 
injury, b) renal replacement therapy, c) 90-day mortality 
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Table 20. AUCs (95% CI) of NGAL, IL-18, and IL-18 * NGAL in prediction of acute kidney injury (AKI), renal 
replacement therapy (RRT), and 90-day mortality 
 AUC (95% CI) 
 AKI RRT 90-day mortality 
NGAL 0.631 (0.579-0.682) 0.827 (0.765-0.889) 0.618 (0.573-0.664) 
IL-18 0.531 (0.479-0.584) 0.598 (0.498-0.697) 0.524 (0.476-0.573) 
NGAL*IL-18 0.603 (0.553-0.654) 0.767 (0.708-0.826) 0.588 (0.542-0.634) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); AUC, Area 
Under the Curve; 95% CI, 95% Confidence Interval; RRT, Renal Replacement Therapy 
 
5.4. Outcome 
 
5.4.1. Length-of-stay (I) 
 
In this study population, the length-of stay (median, days with IQR) in the ICU was 
significantly longer in patients who developed AKI (3.7, 1.9 - 6.4 days) than in patients 
without AKI (1.9, 1.0-4.0 days). Also, the hospital stay was significantly longer in AKI 
patients (12, 6.0 - 22.0 days) compared to patients without AKI (9, 5.0 - 15.0 days). 
 
5.4.2. Health-related quality of life (IV) 
 
In study IV, 1190 of the 1568 patients were alive at six months, and of those, 411 (34.5%) 
had AKI. Of the six-month survivors, 959 (80.6%) answered the EQ-5D questionnaire 
(including 327 patients with AKI). For 774/959 (80.7%) patients, the admission EQ-5D 
was also available (including 268 patients with AKI). There was no difference in the 
characteristics of the six-month EQ-5D respondents and non-respondents. However, the 
patients that had not answered at admission (390/1568) had higher severity scores 
compared to the respondents (day 1 SOFA score 8 (6-10), as compared to 7 (5-9), and 
SAPS II score 40 (31-55), as compared to 35 (26-47)). 
 
The mean change in EQ-5D index from admission to six months was 0.017 for patients 
without AKI, and 0.024 for patients with AKI. The mean difference between the changes in 
patients without and with AKI was 0.007 (-0.314 - 0.045) (P=0.728). 
 
The six-month EQ-5D index and VAS scores of patients with AKI, patients with RRT, and 
patients without AKI, compared to the age- and sex-matched general population are 
presented in Table 21, and the distribution of answers in patients with and without AKI in 
Table 22.   
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Table 21. The EQ-5D index (scale 0-1) and VAS scores (scale 0-100) at six months for patients with acute 
kidney injury (AKI) and renal replacement therapy (RRT) compared to patients without AKI 
 EQ-5D index  EQ-5D VAS  
 Study patients General population Study  
patients 
General 
population 
Patients without AKI 
(N=632) 
0.690 (0.533-1.00) * 0.845 (0.812-0.882) 75 (60-87) 70 (68-77) 
Patients with AKI 
(N=327) 
0.676 (0.520-1.00) * 0.826 (0.812-0.859) 70 (50-83) 69 (68-73) 
Patients with RRT 
(N=85) 
0.676 (0.482-0.802)* 0.845 (0.819-0.882) 65 (50-80)* 70 (68-77) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); RRT, Renal 
replacement therapy; *P <0.001, comparison between the study patients and age- and sex-matched general 
population. Values are presented as median (interquartile range, IQR).  
 
 
Factors that were associated with a good HRQol (equal to the age- and sex-matched 
general population) were explored in a multivariable logistic regression model. Among the 
327 AKI patients who responded at six months only, 1) the EQ-5D index at admission (OR 
(95% CI) 1.042 (1.024 - 1.060)/0.01 points), and 2) the lack of hypertension (OR 2.561 
(1.141 - 5.750), were independently associated with a good HRQol. In comparison in the 
632 patients without AKI only the EQ-5D index at admission was a factor independently 
associated with a good HRQol (OR 1.039 (1.028 - 1.049)/0.01 points).   
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Table 22. The distribution of EQ-5D answers at six-months in patients with and without acute kidney injury 
(AKI) 
 
 Patients 
without AKI 
(N=632) 
% 
Patients with 
AKI 
(N=327) 
% 
Mobility   
I have no problems in walking about 54.3 48.6 
I have some problems in walking about 39.7 43.4 
I am confined to bed 6.0 8.0 
Self-care   
I have no problems with self-care 77.8 72.2 
I have some problems washing or dressing myself 16.6 22.0 
I am unable to wash or dress myself 5.5 5.8 
Usual activities (e.g., work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 59.2 54.7 
I have some problems with performing my usual activities 32.4 34.6 
I am unable to perform my usual activities 8.4 10.7 
Pain/discomfort   
I have no pain or discomfort 47.9 43.4 
I have moderate pain or discomfort 46.5 50.2 
I have extreme pain or discomfort 5.5 6.4 
Anxiety / depression   
I am not anxious or depressed 71.0 73.4 
I am moderately anxious or depressed 26.3 23.5 
I am extremely anxious or depressed 2.7 3.1 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria) 
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5.4.3. Short-term mortality (I) 
 
The overall ICU- and hospital mortality in this population of 2901 adult ICU patients were 
241/2901 (8.3%, 95% CI 7.3% - 9.3%), and 471/2901 (16.2%, 95% CI 14.9% – 17.6%). ICU 
mortality for AKI patients was 175/1141 (15.3%, 95% CI 13.2% - 17.5%)(Nisula et al, 
unpublished data), and hospital mortality for AKI patients was 292/1141 (25.6% 95% CI 
23.0 – 28.2%) compared to 179/1760 (10.2%, 95% CI 8.7 – 11.6%) in patients with no AKI. 
5.4.4. 90-day mortality (I) 
 
The 90-day mortality in the whole study population was 678/2901 (23.4%, 95% CI 21.8% - 
24.9%). By day 90 after admission 385/1141 (33.7%, 95% CI 30.9 – 36.5%) of the AKI 
patients had died compared to 293/1760 (16.6%, 95% CI 14.9 – 18.4%) of patients without 
AKI. Of the patients who received RRT, 106/272 (39.0%, 95% CI 33.1% – 44.9%) died 
within 90-days.  
5.4.5. Six-month mortality (IV) 
 
The crude six-month mortality in the study IV patient population was 378/1568 (24.1%, 
95% CI 21.9 - 26.3%). Of the AKI patients, 224/635 (35.3%, 95% CI 31.5 - 39.1%), and 
154/933 (16.5%, 95% CI 14.1 - 18.9%) patients without AKI, died during 6-months. For 
patients that received RRT, the six-months mortality was 63/162 (38.9%, 95% CI 31.2 - 
46.5%)(IV). Figure 12 illustrates a Kaplan-Meyer survival plot of the 1568 study patients 
(IV) and Table 22 presents 90-day and 6-months mortality for patients stratified into 
different KDIGO stages.  
 
 
 
Figure 12. A Kaplan-Meyer survival plot of the 1568 study patients (IV) Stratified into different KDIGO 
(Kidney Disease: Improving Global Outcomes) stages. 
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Table 23. 90-day and six-month mortality of patients with acute kidney injury (AKI) stratified into different 
KDIGO stages 
 Study I Study IV 
 90-day mortality 
N (%) 
6-month mortality 
N (%) 
Stage 1 146/499 (29.3) 89/280 (31.8) 
Stage 2 79/232 (34.1) 40/119 (33.6) 
Stage 3 160/410 (39.0) 95/236 (40.3) 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); Numbers are 
presented as count (percentage) 
 
 
In the 2901 patients in study I, all stages of AKI were independently associated with 90-
day mortality. See Table 24 for odds ratios. In the same logistic regression analysis also age 
(OR 1.04), non-operative admission (OR 2.21), and highest lactate of the admission day 
(OR 1.17) were independently associated with 90-day mortality.  
 
 
 
Table 24. Odds ratios (95% CI) for acute kidney injury (AKI) stages I-III for association to 90-day mortality 
 OR 95% CI 
AKI Stage I 1.71 1.31 –2.23 
AKI Stage II 1.78 1.26 – 2.51 
AKI Stage III 1.71 1.28 – 2.29 
AKI, Acute kidney injury (by the Kidney Disease Improving Global Outcomes, KDIGO criteria); 
OR, Odds Ratio; 95% CI, 95% Confidence Interval 
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6. DISCUSSION 
 
6.1. Incidence of AKI (I) 
 
The incidence of AKI in the ICU in this study was 39.3%, which is in close agreement 
with four large retrospective studies19,183,217,218 of which two used both RIFLE and AKIN 
criteria19,217, one used AKIN (only Cr)218, and one used RIFLE (only Cr)183. In two of these 
studies19,217, however, the observation period for AKI was shorter (24 hours, and 2 days) 
suggesting a higher incidence result with an observation time comparable to this study (5 
days). Surprisingly the prospective15,166,167,216 studies had the largest variance in reported 
incidences (10.8%15 to 65.8%167). Cruz and colleagues15 reported the lowest incidence of 
10.8% with the RIFLE criteria in a study with 19 ICUs from Italy including mostly small 
hospitals. Of note, in this study the first AKI stage instead of the highest was used for 
incidence calculations possibly explaining the low incidence. Only four years later another 
prospective, a multicentre study167 from Italy also using RIFLE with 576 patients, reported 
a high incidence of 65.8%.  There is no obvious explanation for the vastly different results 
in these two Italian studies. The highest reported incidence of AKI (67.2%) comes from a 
retrospective, single centre study with 5 383 patients16 that defined AKI with the RIFLE 
criteria. In this study, the observation period for development of AKI included the whole 
hospital stay, which might partly explain the high incidence.  
 
Study I was the first to evaluate the incidence of AKI with the KDIGO criteria. Since 
KDIGO combines RIFLE and AKIN by introducing both the “historical baseline Cr” from 
RIFLE and the “small rise of 26.5 µmol/l in Cr” from AKIN, it would be expected to 
increase the number of patients identified to have AKI. This presumption will have to be 
confirmed in future studies, but the result of study I seems to fortify that hypothesis with 
9/1415,19,166,168,183,217-220 of the prior studies reporting lower incidences.  
 
Two studies from Finland have previously reported incidences for ICU treated AKI both 
using the RIFLE criteria. A large retrospective study by Vaara and colleagues220 presented 
a lower incidence of 26.6%, but that particular study was designed to evaluate the 
incidence of RRT, and no urine output data were available and the Cr data were 
incomplete.  Another study by Åhlström and colleagues216 was a prospective study with 
both Cr and UO data available presenting an incidence of 52% for AKI in the ICU. That 
study was, however, a single centre study from a university hospital. As a tertiary care 
centre with complex patients, that same study centre in study I presented an almost 
identical incidence of 53.5%, highlighting the importance of multicentre design in 
epidemiological studies.  
 
The incidences of AKI in the 17 different ICUs in study I varied from 20.7% to 53.5% most 
likely reflecting differences in patient characteristics and variance due to small sample size 
in the smaller study centres.  
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In study I, the population-based incidence of ICU treated AKI was 746/million 
adults/year. The only other study with population based incidence for ICU treated AKI 
reported a very high result of 2900/million/year213: the RIFLE was employed with both Cr 
and urine output criteria, but the reference population included only inhabitants of one 
county area in the USA rather than the whole country. Also, there was unlimited access to 
intensive care in that area, which might have affected the results. This hypothesis is 
supported by the fact that the incidences of other organ failures in that study were also 
exceptionally high. One retrospective study evaluated the population-based incidence of 
hospital treated AKI defined with RIFLE and reported an incidence of 
2147/million/year214. Based on the population-based incidence in study I about 4000 
adults develop AKI during their ICU treatment in Finland every year.  
 
6.2. Risk factors for AKI (I) 
 
In study I, patients that developed AKI were older and more severely ill judged by the 
SOFA score and SAPS II points, as well as the fact that they more often received 
vasoactives, mechanical ventilation, and had a higher admission day lactate. These 
findings are in concordance with a majority of epidemiological AKI studies reporting 
predisposing factors for AKI16,25,166-168. Of chronic comorbidities, hypertension (56%), 
systolic heart failure (14%), and medications suggesting cardiovascular diseases (ACEIs or 
ARBs (43%), aspirin (30%), diuretics (36%), and statins (35%)) were frequent in AKI 
patients in this study in concordance with two other studies reporting cardiovascular 
diseases to be significantly more common in AKI patients167,168. About one quarter of the 
AKI patients had diabetes compared to one fifth of the patients without AKI, which is in 
concordance with previous data165,171. CKD was present in over 10% of AKI patients 
compared to 4% of non-AKI patients and the baseline creatinine of AKI patients was 
significantly higher compared to patients without AKI. CKD has been reported as a 
predisposing factor for AKI in three other epidemiological studies16,25,168. Though the 
studies by Hoste and colleagues16 and Piccinni and colleagues167 found a medical 
admission to be associated with AKI, there was no significant difference in AKI incidence 
between surgical and non-surgical admissions in study I. Similar to several previous 
studies, severe sepsis was significantly more common among AKI patients in study 
I25,166,167.  
 
It was noteworthy in study I that contrast media were more seldom given to patients who 
later on developed AKI both before and during the ICU treatment, and therefore contrast 
medium did not associate with the development of AKI in study I, despite its established 
role as an AKI risk factor323. This suggests that treating physicians in the ICU, and also in 
the emergency departments and hospital wards, seem to acknowledge that contrast media 
should be avoided in patients showing any signs of AKI and in patients with cumulating 
risk factors for AKI.  
 
Over 35% of AKI patients (P<0.001 compared to patients without AKI) received diuretics 
prior to their ICU admission, in spite of the fact that these patients most likely already 
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show signs of AKI (e.g. oliguria) at the time of receiving the diuretics. Including the time in 
the ICU, a majority of all patients (>50%) received diuretics, but this was significantly 
more frequent in patients without AKI. This finding suggests that treating personnel in the 
ICUs might be more aware of the potential disadvantages of diuretics in AKI compared to 
other hospital staff. However, the fact that over 50% of all ICU patients received diuretics 
at some stage leaves room for doubt as to whether diuretics are generally used excessively 
in critically ill patients.  
 
Pre-ICU hypovolaemia and Pre-ICU hypotension were significantly more often observed in 
patients that later on developed AKI.  In addition to probably independently contributing 
to the development of AKI8 these might associate with the significantly increased use of 
colloids (HES or gelatin) in AKI patients. At the time of study I data collection, the most 
recent RCTs187,190 showing a link between HES, excess renal failure, and mortality had not 
yet been published. These studies concluded that HES increased AKI and the need for RRT 
in ICU patients189, and the need for RRT in septic patients190 verifying the observational 
result of this study. Despite the fact that these data were not available, the use of colloids in 
the ICU in this study was significantly more rare in patients that developed AKI than in 
those that didn’t. 
 
Most of the studies reporting predisposing factors to AKI have been observational studies 
and therefore cannot establish causality (as opposed to RCTs). Logistic regression as a 
statistical method can be used to strengthen the findings of observational studies, but 
results should still be interpreted with caution. Only the studies by Hoste and colleagues 
and Medve and colleagues tested factors associated with AKI in a logistic regression model. 
They found that CKD, medical admission, malignancy, and SOFA score (Hoste), and SAPS 
II, Cr on admission and sepsis (Medve) to be independently associated with the 
development of AKI. Of these, only CKD was also an independent factor in study I. The 
other independent risk factors in study I (pre-ICU hypovolaemia, pre-ICU use of diuretics, 
pre-ICU use of colloids) were not tested in any of the other studies.  
 
 
6.3. Novel biomarkers of AKI 
 
6.3.1. Neutrophil gelatinase-associated lipocalin (II) 
 
Study II showed that urine NGAL does not have adequate predictive value concerning AKI 
(AUC 0.733) or 90-day mortality (AUC 0.634) in critically ill adults. NGAL was associated 
with RRT (AUC 0.839), but conversion of this result into clinical use is complicated.  
 
Results from studies evaluating the power of NGAL in predicting AKI in children 
undergoing cardiac surgery have been very promising and have set wide scale expectations 
for NGAL as an AKI biomarker. The less optimistic results in adults (pooled AUC of 0.775 
in a systematic review134) undergoing cardiac surgery suggest, however, that adult patients 
have confounding factors concerning NGAL. Critically ill patients have a wide range of 
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chronic illnesses and the type and time of the kidney insult is variable. In these patients, 
the performance of NGAL has been clearly incoherent and yet unclear based on existing 
studies. In ten studies evaluating NGAL in the prediction of AKI in the ICU the AUCs range 
from 0.48144 to 0.956139. Mårtensson and colleagues138 and Constantin and colleagues139 
reported good to excellent results, but these were the smallest ICU studies with 25 and 88 
patients, and the study by Mårtensson and colleagues only included septic patients. The 
study by De Geus and colleagues has been the largest study with 632 patients on adult ICU 
patients prior to study II141, reporting an AUC of 0.77 for plasma and 0.80 for urine NGAL 
in AKI prediction.  
 
Half of the studies actually report AUCs (0.68 to 0.78)112,127,140,141,145, which are quite 
consistent with the results in study II. Also, the systematic review and meta-analysis from 
2009 calculated a comparable pooled AUC of 0.728134 for NGAL in prediction of AKI in 
critically ill patients supporting the findings of study II.   
 
The majority of the seven studies that have evaluated the performance of NGAL in 
prediction of RRT112,135,140-142,144, reported AUCs, which were comparable (0.78135 to 
0.82140) to the AUC of 0.839 in study II. Very weak performance for NGAL with AUCs of 
0.26 from urine and 0.47 from plasma were reported by Royakkers and colleagues144, but 
the numbers of endpoints in that study were really small (N=14).  
 
Even with a quite good statistical association of NGAL with initiation of RRT in study II, 
the conversion of these results into clinical use is challenging for several reasons. First, the 
criteria for RRT initiation was not uniform1 but rather based on individual choices by the 
treating physicians. Second, even with an association of NGAL with initiation or RRT, it is 
still unclear if the patient will benefit from this treatment as data on the optimal timing of 
RRT are still lacking269, and it is difficult to evaluate the impact of RRT on the prognosis of 
these patients. The fact that NGAL associates with the decision to initiate RRT but not with 
AKI could reflect a poor or worsening general condition of these patients, rather than just 
poor kidney function.  
 
Of the six studies that have assessed NGAL in mortality prediction111,112,135,140-142, only one 
study from Finland by Linko and colleagues142, used a long-term endpoint of 90-day 
mortality. That study reported comparable poor results (AUC of 0.58) to study II (AUC 
0.634). Two studies used hospital mortality as an endpoint and also reported suboptimal 
AUCs of 0.389135 to 0.64141. The study with 339 patients by Doi and colleagues111 was the 
only one reporting a good AUC (0.83) for NGAL in mortality prediction, but 14-day 
mortality was found to be clinically irrelevant.  
 
Heterogeneity among the studies on NGAL concerning study design, timing of samples, 
and the amount samples, is observed possibly explaining the incoherent results. The 
incidence of AKI in these studies varies from 14%140 to 72%127 reflecting probable 
differences in patient populations and the definition of AKI324. Also, it seems that 
immunoassays with different antibodies are not uniform in their performance in 
measuring NGAL325,326. The existing different molecular forms of NGAL and the lack of 
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knowledge in their measurement severely complicate NGAL’s current use as a 
biomarker135.  
6.3.2. Interleukin 18 (III) 
 
Study III showed that IL-18 has no prognostic power concerning AKI, RRT, or 90-day 
mortality in critically ill adult patients.  
 
IL-18 yielded an AUC of 0.586 in predicting new AKI during the next 48 hours, which is in 
concordance with four111,112,154,156 of the other studies of IL-18 in an ICU environment. The 
numbers of patients in those four studies vary from 20154 to 528112 and they report AUCs 
from 0.55112 to 0.62156. Only the study by Parikh and colleagues152, including 138 lung-
injury patients, reports a marginally better AUC of 0.73 in prediction of AKI. Parikh and 
colleagues also reported an independent association of IL-18 with development of AKI (OR 
ranging from 2.3 to 3.7), which was also true in study III with an OR (95% CI) 1.003 
(1.001-1.005). However, the overall AUC of the model in study III was poor (0.693) and 
changed only marginally when including IL-18 (0.697) suggesting no apparent role in AKI 
diagnostics. The recent meta-analysis on urine IL-18 by Liu and colleagues reached a 
pooled AUC of 0.66 for IL-18 in prediction of AKI in critically ill patients159 which is in 
concordance with the results of study III.  
 
It has been previously reported that IL-18 is an early marker of kidney injury that starts to 
rise in 2-4 hours, peaks at 12 hours, and stays elevated for 24-48 hours after the initial 
insult to the kidneys130,152. With most ICU patients there is significant delay between the 
onset of illness and admission to the ICU, and the early onset of the IL-18 rise might be 
one factor explaining its poor performance as a kidney injury marker in this group of 
patients. This hypothesis is supported by the finding in study III (figure 10) that the 
median concentration of IL-18 in AKI patients was decreasing from admission to 24 hours 
suggesting an earlier peak in IL-18.  
 
Reliable data on the association of IL-18 with RRT have been missing. One study reported 
an AUC of 0.73, but in this study only 19 patients reached the endpoint of RRT and the 
observation period was substantially long (19 days)112. The study by Siew and colleagues 
presented a composite endpoint of death or dialysis during 28 days with only 17 patients 
fulfilling this endpoint. The adjusted OR for IL-18 was 1.76156, but IL-18 was not significant 
for predicting dialysis alone. The AUC (0.655) for IL-18 in prediction of RRT in study III 
doesn’t support the use of IL-18 for this purpose.  
 
Study III found no association with urine IL-18 and 90-day mortality (AUC 0.536). The 
largest study on IL-18 prior to this, by Endre and colleagues112 with 528 patients, reported 
hardly any better results (AUC 0.68). Doi and colleagues111 found a slightly promising AUC 
of 0.83, but similar to the study by Endre and colleagues, the follow-up time for the 
endpoint chosen was too short to be clinically significant (14 days and 7 days). Altogether, 
data do not support the use of IL-18 in the prediction of mortality. 
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6.3.3. NGAL compared to IL-18 (III) 
 
Like in the individual studies II and III, analyses of the admission NGAL and IL-18 from 
patients with both samples available showed that IL-18 is inferior to NGAL in predicting 
all of the chosen endpoints AKI, RRT, and 90-day mortality. However, even with NGAL the 
results were not compelling enough to be sufficient for clinical use (II and III). Siew and 
colleagues also compared NGAL to IL-18 and had comparable results156. They also found 
that adding IL-18 to NGAL didn’t improve the AUC for detecting AKI. In study III it was 
chosen to multiply NGAL with IL-18, but the resulting AUC was inferior to that of NGAL 
alone in predicting all the endpoints (AKI, RRT, 90-day mortality).  
 
6.4. Outcome 
 
6.4.1 Health-related quality of life (IV) 
 
Study IV showed that the HRQol of patients with AKI is not different from that of patients 
without AKI at ICU admission or at 6 months after ICU treatment. Moreover, the HRQol of 
both AKI and non-AKI patients is lower than the age- and sex-matched general population 
already at admission. And nor does it change significantly during critical illness.   
 
Data on the HRQol of AKI patients are scarce with the exception of RRT patients. A recent 
single centre study by Hofhuis and colleagues20 concluded that the HRQol of AKI patients 
was already lower at ICU admission compared to general population. Also, the HRQol at 
six months for AKI patients was almost similar to those without AKI (lower only in vitality 
and general health dimensions in AKI patients). 
 
Despite their poorer health judged by the EQ-5D index, the patients in study IV (with AKI 
and without AKI) perceived their HRQol to be as good as that of the general population. 
Abelha and colleagues drew similar conclusions in a study with postoperative AKI patients 
with lower health scores but a perception of excellent health293. 
 
In study IV the HRQol of RRT patients was equal to that of AKI patients, but opposite to 
the results of the two earlier Finnish studies220,282, RRT patients in study IV perceived their 
health (judged by the VAS score) to be significantly lower than that of other ICU patients.   
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6.4.2. Mortality (I, IV) 
 
Though fixed and long-term outcomes have been recommended327, the majority of studies 
on incidence and outcome of AKI have only reported short-term mortality rates for AKI 
patients15,16,19,25,166,167,183,216-219,297. The ICU mortality for patients with AKI ranged from 
28.4%183 to 54.0%297 in previous studies, and the ICU mortality of 15.3% in study I was 
significantly lower. Also, the hospital mortality rate for AKI patients (26.5%) in study I was 
one of the lowest among all studies (13.3% to 49.1%)16,19,25,166,183,216-219. None of the other 
studies reported 90-day mortality rates and only three evaluate the 6-month mortality of 
patients with AKI20,293,297. The six-month mortality for AKI patients in study IV (35.3%)  
was lower than in the other studies ranging from 38.0%293 to 58.5%297. 
 
Both short- and long-term mortality rates are low in studies I and IV compared to previous 
studies. Differences in study designs and patient populations explain some of the variation 
between studies. These studies did not consistently report severity scores, but on the basis 
of the given SAPS II points there was a large variation on how severely ill the ICU patients 
were; SAPSII points for patients without AKI ranged from 18293 to 52297 and for patients 
with AKI from 31293 to 6225 in the studies reporting outcome for AKI patients. The study by 
Abosaif and colleagues had the highest ICU and 6-month mortality, but also very high 
SAPSII scores for patients with and without AKI (51-52 points)297. Variations in the 
severity of illness most likely have an effect on not only the incidence of AKI, but also the 
outcome of the patients. In some countries or areas there is unlimited access to intensive 
care treatment. In Finland this is not the case, and ICU treatment has to be allocated for 
patients who are believed to benefit the most from it. This often means that moribund 
patients with poor chance of survival are not admitted to ICUs. This patient selection 
might improve the calculated outcomes of ICU patients. However, it has been shown that 
the outcomes of Finnish intensive care patients are generally good312, and the overall 
hospital mortality of 18.4% (years 2001-2008) is low compared to two large European 
studies328,329 with comparable severity of illness scores.  
 
Bell and colleagues showed that most of the deaths among AKI patients occur within about 
60 days330. The Kaplan-Meyer survival curve of patients from study IV supports this 
finding and suggests that a follow-up of less than this would be insufficient when assessing 
mortality. Furthermore, study I shows that if using either ICU- (15.3%) or hospital-
mortality (26.5%) as the endpoint the total number of deaths would be severely 
underestimated (90-day mortality 33.7%). 
 
Extrapolated from the population of study I, there are roughly 8000 ICU patients annually 
in Finland comparable to the FINNAKI study population (adult, ICU LOS >24 hours, non 
intermediate care, see inclusion and exclusion criteria of study I).  Derived from the 
recently published study on mortality attributable to AKI in the ICU298, about 350 lives 
among these patients could be saved in Finland every year if AKI could be avoided.   
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6.5. Methodological considerations 
 
6.5.1. Validity, bias, and precision (I-IV) 
 
Study I was the largest prospective study on the epidemiology of AKI in the ICU to date. 
The large sample size, multi-centre setting, and prospective design increase the validity of 
the study. Also, the study period of 5 months is estimated to be adequate, particularly 
when no evidence of a seasonal variation in the incidence of AKI exist. Furthermore, the 
population in the areas of the participating hospitals encompasses the majority (85%) of 
the adult population in Finland, and 17 out of the 25 intensive care units in Finland. All 
patients admitted to the ICUs during the study period were screened for eligibility. The 
data collection was extensive and relied on an automated and validated prospective 
database and audited CRF data. The latest definition of AKI with both the Cr and Urine 
output was utilized, which increments to the internal validity of these studies (I-IV). 
However, the limitations of an observational study persist. No certain causalities can be 
proven with this study design.  
 
Due to the substantial size of the study I population and the multicentre setting, these 
results are inclined to be well generalizable to other cohorts. However, as can be shown by 
the large variation in the incidences of AKI in different study centres, some of these results 
might not compare to individual ICUs, but rather larger cohorts. Also, because of the 
ethnic structure of the Finnish population, these data are almost exclusively based on the 
Caucasian race, which should be acknowledged when applied to other ethnic groups. 
Finland represents a welfare state with a high-quality universal public healthcare system, 
generally a high level of education, and narrow socioeconomic gradients compared to 
many other countries331. This should also be acknowledged if implementing these results 
(I-IV) into other populations. 
 
These studies (I-IV) most likely present only minor selection bias due to the complete 
screening of patients. The use of a deferred consent policy further reduces selection bias. 
In studies II and III an attempt was made to avoid bias by selecting the included laboratory 
samples at random and in a blinded fashion. Likewise, in study IV only centres with an 
adequate number of follow up data were included to avoid bias. The fact that urine samples 
cannot be collected from anuric patients presents a selection bias in studies II and III.  
 
When assessing information bias, the data in these studies (I-IV) can generally be 
considered reliable due to the collection methods (see methods, data collection). However, 
about 50% of the variables were collected with the CRF, which presents an elevated risk of 
biased data as the CRF is filled out manually by the ICU staff. The study specific laboratory 
samples in studies II and III were assayed by the same individual in large batches with 
commercially available and validated kits, which reduces bias. Collecting data with 
questionnaires especially using proxies can present a bias. However, the EQ-5D has been 
validated in ICU patients319 and information provided by proxies has proven reliable316.  
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Confounding bias is unavoidable in an observational study assessing effects and exposures. 
It is acknowledged in these studies (I-IV) that no certain causalities can be drawn between 
associated factors. Multivariable logistic regression techniques were used in an attempt to 
minimize the effect of confounders. 
 
In study I the targeted precision (95% CI ± 2.0%) in the incidence of AKI was achieved. 
Also the 95% CIs of the AUCs in studies II and III were within preferred limits with the 
exception of the CIs in AUC of IL-18 predicting RRT due to a small number of endpoints.  
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6.6. Limitations 
 
Several limitations in these studies (I-IV) should be addressed. The FINNAKI study was an 
observational study and therefore only associations can be shown, and no absolute 
causality. In study I only AKI in the ICU was evaluated. The incidence of AKI outside ICUs 
is, however, also substantial. The screening period for AKI was 5 days, which rules out the 
possibility to identify AKI developing after that.  However, according to available data the  
majority of AKI patients reach their highest AKI class during the first few days of their ICU 
stay (median 2 days IQR 1-3 to 1-7 days)16. Furthermore, according to a study in Finland 
the mean length of stay in the ICU was 3.1 +/- 5.3 days (median 1.3 days; quartiles 0.8 - 
3.0 days)332 also supporting the hypothesis that 5 days is a sufficient time to recognize 
most cases of AKI. When applying the KDIGO criteria for AKI, the MDRD equation was 
used to estimate a baseline creatinine when a measured value was not available. The use of 
any surrogate or estimated baseline Cr will result in some bi-directional misclassification 
of AKI. Studies have shown that this misclassification is more likely to occur in mild AKI 
than in more severe AKI42,47,48,333. Still, the latest consensus criteria for diagnosing and 
staging AKI (KDIGO)1 includes a baseline Cr in the definition of AKI. Based on existing 
data, despite known shortcomings in the MDRD equation, it is the recommended method 
for estimating Cr by the Acute Dialysis Quality Initiative (ADQI)334, and also the method 
most commonly used in studies regarding AKI46. In studies III and IV, sensitivity analyses 
were performed to exclude any bias from estimating baseline Cr. Concerning acute events 
preceding AKI, data on hypotension, hypovolaemia, low cardiac output, and massive 
transfusion were only recorded before the ICU admission. Since the majority of AKI 
patients developed AKI during the first few days in the ICU, this is not considered as a 
major factor of bias. Because of limitations in data collection it was not possible to 
differentiate between the different types of colloids (HES, gelatin, albumin) in study I. 
Therefore colloids before ICU admission included HES or gelatin and after ICU admission 
also albumin.  
 
In studies II and III the laboratory samples were not from consecutive patients, but taken 
out from storage in random boxes without any knowledge of patient outcomes of 
properties. As shown in study II, patient demographics and numbers of outcomes were 
comparable to the original FINNAKI study cohort. The urine samples in studies II and III 
were not centrifuged prior to storage. Data show that centrifuging does not affect the 
stability of NGAL335-337 or IL-18338 in urine. It was chosen in studies II and III to report 
NGAL and IL-18 as absolute values and not normalized to urine Cr, though some 
studies159,339 suggest that normalization would improve results. However, this is 
complicated because the amount of Cr excretion in different situations is highly variable340.  
 
In study IV, only patients from 10 out of 17 study centres were included due to lacking 
follow-up EQ-5D data. Study centres with over 70% response rate were chosen to avoid 
selection bias. Although excluding 7 sites, some data was still lacking: the EQ-5D data was 
available for 80% of the patients at six months. The admission EQ-5D was not available for 
19% of the 6-month respondents.  
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6.7. Clinical implications 
 
 
AKI is very common among critically ill adult patients. This was the first study to evaluate 
the incidence of AKI in a multicentre setting in Finland.  
 
No specific treatment for AKI exists. Preventing the development or worsening of AKI by 
removing risk factors when possible is currently the main method of reducing the 
incidence of AKI. It is important to perceive the additive nature of chronic comorbidities 
and acute events as risk factors for AKI. The total risk of AKI for each patient is the sum of 
all the different potential risk factors concurrently involved. All critically ill patients are at 
elevated risk of AKI.  
 
The use of many nephrotoxic substances (e.g. diuretics and colloids) in patients that 
developed AKI suggests that physicians could be better aware of potentially harmful drugs 
in patients at risk of AKI. 
 
Aiming to reduce the incidence of AKI is important because AKI associates with 
significantly increased short- and long-term mortality - even in patients with the mildest 
stage of AKI. Because of this high mortality, patients with severe AKI and patients with 
AKI accompanied with other organ failures should be treated in appropriately equipped 
units with the possibility of haemodynamic, volume status, laboratory, and urine output 
monitoring   
 
The health-related quality of life of patients admitted to ICUs is lower than that of the 
general population. Surprisingly, critical illness has no further effect on the HRQol of these 
patients. Furthermore, although AKI complicates and prolongs treatment, the surviving 
AKI patients’ HRQol is as good as that of those who didn’t have AKI. Most importantly, 
despite a lower objectively measured health, both patients with and without AKI perceive 
their quality of life as equal to that of the general population.  
 
Urine NGAL, or IL-18, do not provide additional assistance in the prediction of ICU patient 
AKI or mortality. NGAL predicts the need for RRT, but since no unified criteria for RRT 
initiation or knowledge of the most beneficial timing, dose, and modality of RRT exist, this 
finding currently lacks clinical significance. Thus, urine NGAL or IL-18 should not be used 
in the prediction of AKI, RRT, or 90-day mortality in critically ill adult patients. 
 
AKI is an important syndrome with significant consequences. All physicians should be 
familiar with the concept of AKI emphasizing those working in emergency departments, 
operating theatres, and intensive care units.  
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6.8. Future perspectives 
 
 
The fundamental constraint in all AKI studies is the shortcomings in the way acute kidney 
injury can be defined and diagnosed. The current diagnostic criteria (gold standard) for 
AKI rely on creatinine and urine output in the absence of anything better. Cr and UO both 
are surrogates for glomerular filtration – in other words functional markers. As functional 
markers they lack sensitivity, specificity, and rapid timing to identify injury in the kidneys. 
The delay between the onset of injury and identifiable signs of AKI (loss of function) causes 
the therapeutic window, during which potential interventions could be tested or carried 
out, to be missed. More accurate ways of rapidly identifying acute damage in the kidneys 
are needed.  
 
Currently medical imaging does not play a significant role in AKI diagnostics, but can 
mainly provide information on pre-renal (vascular) or post-renal (hydronephrosis) causes 
of AKI, and visualize macroscopic processes (malignancy, hematoma) influencing the 
kidneys.  With evolving techniques, there is a hope for kidney imaging that would identify 
more subtle on-going processes or assess function. Renal blood flow can already be 
measured noninvasively with cine-phase contrast magnetic resonance imaging90. Doppler- 
and micro-vesicle contrast-enhanced ultrasonography are relatively new methods that may 
provide more information on renal perfusion in the future341-343.  
 
Though it would provide important information on AKI, acquiring kidney biopsies of all 
ICU patients is too invasive and complex for everyday clinical use with the current 
methods. Adequate creatinine clearance measurements would provide a clear picture of 
the functional capacity of the kidneys. Perhaps in the future, with method development, 
these procedures can be performed bedside in the ICU rapidly and inexpensively. GFR 
measurements alone would still, however, fail to provide any information on injuries that 
don’t affect function. Are they relevant in terms of outcome? That remains to be studied.  
 
An inaccurate gold standard344 for AKI leads to a fundamental dilemma in biomarker 
studies: When comparing new biomarkers against Cr and UO markers that are more rapid 
in identifying AKI as we know it can possibly be revealed, but nothing new will be 
discovered in terms of identifying AKI outside the current criteria. Some data suggests that 
patients that have elevated damage markers but no loss of kidney function i.e. no AKI with 
the present criteria are at elevated risk of adverse outcome, such as RRT and mortality345.  
This might represent a population of patients that have “subclinical AKI”, and recently the 
addition of damage markers to the criteria for AKI was suggested14. 
 
It is very interesting that NGAL, for example, predicts AKI in otherwise healthy children 
undergoing cardiac surgery114, but lacks that power in critically ill patients. Just because 
the results against the current AKI criteria are poor, doesn’t mean we should stop looking 
at NGAL or other markers in the ICU. However, wide scale further work is needed to 
identify what it actually is, that NGAL or the other somehow promising biomarkers react to 
or predict, and in which patients they should be used.  
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In any case the critically ill will always be an especially challenging group of patients 
concerning kidney injury biomarkers. First, due to significant heterogeneity concerning 
characteristics such as age, permanent illnesses, and type and severity of the acute illness. 
Second, because there rarely is a single identifiable insult to the kidneys but many taking 
place simultaneously, or possibly ongoing for days and with varying intensities. The 
identification of troponins to diagnose myocardial injury was a well-known success story in 
cardiology. However, an acute coronary event most often presents itself with known 
symptoms unlike AKI. Maybe with extensive research it will be learned bit by bit to 
construct a pattern of markers together identifying different pathophysiological processes 
causing AKI, markers predicting the severity and evolution of AKI, and markers predicting 
recovery or little chance of recovery from AKI. 
 
Constructing AKI risk stratification models on the basis of existing data and implementing 
the models to clinical use could still increase awareness of AKI risk factors and help to 
further reduce the incidence of AKI. Still, more studies on factors predisposing to AKI are 
needed. The association of HES with AKI has been evaluated in two large RCTs189,190. 
Similar studies on e.g. haemodynamics, fluid balance, and drugs are wanted. Optimal 
timing, modality, and dose of RRT also remain unknown and require examination in 
further studies.  
 
Establishing knowledge of a biomarker sensitive to predict AKI early on could lead to a 
clinical practice to measure this marker in emergency departments, operating theatres, or 
even hospital wards, and together with risk stratification models to guide admission to an 
ICU or treatment in general e.g. use of contrast media, antibiotics, or other potential AKI 
risk factors. Identifying early markers for AKI would also be crucial for planning RCTs 
concerning factors preventing AKI.  
 
Interesting results on certain genetic variance predisposing patients to AKI346, or 
protecting from AKI176, should be further tested in studies with preferably large-scale 
genotyping. This is currently expensive and time consuming, but in the future AKI genetics 
will probably be an important field of extensive research. 
 
Most of all, the basis of profound understanding of acute kidney injury would be for the 
pathophysiology of AKI to be completely unravelled. This would generate a logical path to 
identifying the risk factors, developing new diagnostic markers, and testing specific drugs 
for prevention and treatment of AKI.  
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7. CONCLUSIONS 
 
 
1. The incidence of ICU treated AKI with the KDIGO criteria was 39%, and the population-
based incidence of AKI in adult ICU patients 746 / million / year. Comparison to previous 
studies was difficult because of large variation in study designs. 
 
2. Patients who developed AKI were older, more severely ill, and had more chronic 
illnesses and medications than patients without AKI. Events such as severe sepsis, 
resuscitation, hypovolaemia, hypotension, low cardiac output, massive transfusion, and 
emergency surgery were more common in AKI patients than other patients. In this 
population, diuretics, colloids (HES or gelatin), and hypotension before ICU admission, as 
well as chronic kidney disease, were independently associated with AKI. 
 
3. Urine NGAL had poor association with the development of AKI and 90-day mortality in 
critically ill patients. Urine NGAL had a statistical association with the initiation of RRT, 
but as uniform criteria for initiation of RRT and data on the most beneficial timing of RRT 
are lacking, the transformation of this result into clinical practice is complicated.   
 
4. IL-18 did not predict AKI, initiation of RRT or 90-day mortality in critically ill adult 
patients, and should not be used clinically for these purposes.  
 
5. The HRQol of patients admitted to ICUs was lower than that of the age- and sex-
matched general population already before ICU admission. The HRQol of patients who 
suffer from AKI remained unchanged during critical illness and was not different from that 
of patients without AKI six months after ICU admission. Despite their lower HRQol AKI 
patients (in exception to RRT patients) felt their health was similar to the general 
population.  
 
6. Although both 90-day (34%) and six-month mortality (35%) in patients with AKI were 
high, mortality among AKI patients in Finland seemed to be lower than in several other 
countries. 
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